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Abstract: 
 
Chronic myeloid leukemia (CML), a cancer originating in the bone marrow, causes excessive 
proliferation of myeloid cells. The genetic signature of the disease is the Philadelphia 
chromosome, created by a translocation between chromosomes 9 and 22 t(9;22). This 
translocation results in BCR and ABL genes fusing together. The chimeric gene product, 
BCR-ABL, is a deregulated tyrosine kinase that promotes cell proliferation and survival. The 
majority of inhibitors targeting BCR-ABL are kinase inhibitors directed against its ATP 
binding site. Imatinib, the first selective ATP-competitive targeted BCR-ABL inhibitor, is 
successful in treating most cases of early-phase CML. Nonetheless, some patients either do 
not respond, or develop resistance to the drug. To combat these problems, second-generation 
BCR-ABL inhibitors were developed, including Nilotinib and Dasatanib. It is noteworthy 
that none of these drugs is effective against T315I gatekeeper mutation. There have been 
efforts to develop kinase inhibitors with new modes of action. In this thesis, we highlight the 
development of ‘non-ATP competitive allosteric kinase inhibitors’ that inhibit kinase activity 
by binding to a site remote from the active site of the kinase. In native ABL, the N-terminus 
is myristoylated, this N-myrisotyl moiety (a small hydrophobic chain of 14 carbons) blocks 
the autophosphorylation activity of ABL as it inserts into a hydrophobic pocket in the kinase 
domain (Myristoyl Binding Pocket - MBP). This discovery stimulated us to develop sets of 
myristate analogues as allosteric inhibitors of BCR-ABL that bind selectively and in high 
specificity to the (MBP) of the ABL kinase, where a myristoyl tail is missing in the 
oncoprotein BCR-ABL product. Those analogues were synthesized, purified, characterized 
and screened for their activity in a cell-based auto-phosphorylation assay and their 
clonogenicity potential was also evaluated. Initial in vitro results demonstrate the usefulness 
of this approach and reveal the identification of myristate derivatives that inhibit BCR-ABL 
autophosphorylation activity of the native and mutated BCR-ABL carrying the "gatekeeper" 
mutation T315I. in this work we discuss the discovery of novel compounds (MAJY-12, -26, -
43 and -72) that display improved inhibitory potency against the auto-phosphorylation of 
BCR-ABL. 
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1. Introduction 
 
1.1. Chronic myelogenous leukemia  
 
Chronic myelogenous leukemia (CML) is a type of myeloproliferative disease that affects the 
bone marrow, in which excess red blood cells, granulocytes, and/or platelets are produced. 
[1]
 
CML is a rare disease and accounts for about 15-20% of all leukemias. Clinically, the disease 
progresses through three distinct phases, referred to as chronic or stable, accelerated, and blast. 
CML is usually diagnosed during the early chronic phase of the disease. The chronic phase is 
characterized by expansion of cells of the granulocytic lineage that retain their ability to 
differentiate. Most patients are diagnosed at this stage as a result of an increased number of 
mature granulocytes in the peripheral blood, weight loss and splenomegaly. This phase lasts 
approximately 5 years on average and then the disease progresses to the accelerated phase and 
the blast crisis phase. These later phases are characterized by the accumulation of immature 
blasts in the bone marrow and the peripheral blood and loss of hematopoietic cell 
differentiation (Figure-1.1). 
[2, 3, 4]
 Disease progression is caused by the accumulation of 
molecular abnormalities, which lead to a progressive loss of the capacity for terminal 
differentiation of the leukemic clone. 
[5]
  
 
Figure-1.1: Disease progression in chronic myeloid leukemia. [3] 
3 
 
1.2. Philadelphia chromosome 
 
CML disorder associated with a characteristic chromosomal translocation called the 
Philadelphia (Ph) chromosome, in which parts of two chromosomes, 9 and 22, swap places. 
This reciprocal chromosomal translocation is designated as t(9;22) in which the ABL 
("Abelson") gene on chromosome 9 fuses to the BCR ("breakpoint cluster region") gene on 
chromosome 22. 
[6]
 The result of the reciprocal translocation is the BCR-ABL gene, which is 
located on the shorter chromosome 22. 
[7]
 The BCR-ABL chimeric oncogene encodes the 
protein p210 or sometimes p185 (p stands for “protein” and the numbers represent the 
molecular weight in kDa) (Figure-1.2) 
[8]
. The presence of the Ph chromosome is the 
cytogenetic hallmark of CML disease. 
 
Figure-1.2: Chromosomal Translocation t(9;22) leading to BCR-ABL fusion [5] 
 
1.3. BCR-ABL tyrosine kinase 
 
The ABL proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase that has 
been implicated in processes of cell differentiation, cell division, cell adhesion, and stress 
response. Under normal conditions, c-ABL exists in a regulated state with very low kinase 
activity. Consequently, the BCR-ABL gene generates a fusion protein, BCR-ABL, with 
deregulated tyrosine kinase activity, autophosphorylates BCR-ABL and activates multiple 
signal transduction pathways, leading to alterations in the proliferative, adhesive, reducing 
growth factor-dependence, apoptosis (Figure-1.3) and abnormal interaction with extra-cellular 
4 
 
matrix and stroma, 
[9]
 with all of these events dependent on the tyrosinekinase activity of the 
BCR-ABL protein. 
[5, 10, 11]
 BCR-ABL is involved in DNA repair, causing genomic instability 
and potentially leading the feared blast crisis in CML. 
[12] 
 
 
 
 
 
 
 
 
 
Figure-1.3: Mechanisms implicated in the pathogenesis of CML. [13] 
 
1.4. The BCR-ABL oncogenetic pathway   
 
ABL tyrosine kinase activity is constitutively activated by the juxtaposition of BCR so 
favoring dimerization or tetramerization and the subsequent autophosphorylation. This 
increases the number of the phosphotyrosine residues on BCR-ABL and, as a consequence, 
the binding sites for the SH2 domains of other proteins. 
[14] 
 
Figure-1.4: Autoregulation of BCR-ABL. Helix I (red bar) and oligomerization domain (black) in BCR domain 
are shown along with SH1, SH2 and SH3 domains. Tyrosines at linker and active sites are highlighted [15]. 
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The abnormal interactions between the BCR-ABL oncoprotein and other cytoplasmic 
molecules lead to the disruption of key cellular processes. Some examples could be 
represented by the perturbation of the Ras-MAP kinase leading to increased proliferation of 
the JAK-STAT (signal transducer and activation of transcription) pathway leading to impaired 
transcriptional activity and of the PI3K/Akt pathway resulting in increased apoptosis. All 
activated signaling pathways converge into a unique terminal point: loss of control of 
proliferation and expansion of the leukemic clone (Figure-1.5). 
[14]  
 
 
Figure-1.5: Schematic representation of the molecular pathway activated by BCR-ABL. [14] 
 
1.5. Pharmacologic inhibitors of kinase activity  
 
The deregulation of tyrosine phosphorylation seems to be a critical abnormality in malignant 
transformation, therefore the inhibition of tyrosine phosphorylation represents an attractive 
strategy for controlling unregulated growth and aberrant malignant behavior. However, target 
specificity is an important part of this strategy. High-throughput pharmaceutical technology 
has led to the development of families of small molecules that selectively inhibit specific 
6 
 
tyrosine kinases. 
[15]
 Inhibitors of kinase activity are characterized as:  
 
(1) Type I, or “DFG-in” (ATP) competitive inhibitors, which directly compete with ATP in 
the ATP-binding site. 
(2) Type II, or “DFG-out” ATP competitive inhibitors, which, in addition to binding the ATP 
binding site, also engage an adjacent hydrophobic binding site that is only accessible when the 
kinase is in an inactivated configuration. 
(3) Non-ATP competitive inhibitors: 
i) ‘Allosteric inhibitors’ that bind to a site remote from the active site and inhibit 
kinase activity. 
[16]
  
ii) Substrate competitor inhibitors such as ON012380 compound that interacts with the 
substrate-binding sites of these kinases. 
[17]
 
 
1.6. Imatinib mesylate - First generation BCR ABL kinase inhibitor 
 
The majority of inhibitors targeting BCR-ABL are kinase inhibitors directed against its ATP 
binding site. 
[18]
 Imatinib mesylate (Signal Transduction Inhibitor-STI571; Gleevec), a drug 
introduced to the clinic, that is specific for the ABL, platelet derived growth factor (PDGF) 
receptor and KIT tyrosine kinases.
[11, 19]
 Imatinib Inhibits the activity of BCR-ABL by binding 
to its ATP site and an adjacent allosteric site to effectively lock the kinase in an inactive 
conformation (Figure 1.6). 
[20]
  By using X-ray crystallography, it was found that Imatinib 
binds to a catalytically inactive conformation of the ABL kinase domain,
 
often referred to as 
the ‘DFG-out’ conformation, 
[17] 
in which the highly conserved Asp–Phe–Gly (DFG) triad is 
flipped out of its usual position in active kinase conformations, 
[21] 
partially occluding its ATP-
binding site.  
7 
 
 
Figure 1.6: Imatinib (STI-571): an example of small-molecule inhibition of protein kinases (a) The structural 
formula of Imatinib. (b) Analysis of the crystal structure of the Abl kinase domain in complex with Imatinib. [22] 
 
Imatinib binds in the cleft between the amino- and carboxy-terminal lobes of the ABL kinase 
domain via number of hydrophobic and hydrophilic interactions, which stabilizes the Imatinib 
BCR-ABL complex and prevents ATP from reaching its binding site. Thus it prevents the 
switch to the active conformation of BCR-ABL, thereby blocking signal transduction (Figure-
1.7). 
[23, 24] 
Imatinib binds to Thr-315 (a conserved residue that is critical for recognition) 
located near the ATP binding pocket and controls access to the hydrophobic pocket, leading to 
its designation as a “gatekeeper” residue. 
[25, 26] 
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Figure-1.7: ABL kinase domain structure bound to Imatinib [24] 
 
1.6.1. Resistance to Imatinib (“Gatekeeper” T315I mutation) 
 
In spite of the clinical response of patients in the chronic phase CML, the majority of patients 
relapse upon Imatinib therapy acquiring resistance against further therapy with Imatinib. 
[27-29]
 
Resistance to Imatinib is mainly related to point mutations in the BCR-ABL kinase domain 
which reduce the binding affinity of Imatinib to the ATP-binding domain by direct steric 
interference or by destabilizing the “DFG-out” conformation of the activation loop that is 
required for high-affinity Imatinib binding. 
[25]
 Point mutations also cause amplification of 
BCR-ABL and decrease cellular uptake or drug metabolism. 
[17]
 The most disturbing mutants 
of the BCR-ABL that induce resistance to Imatinib, is the “gatekeeper” T315I mutation 
(substitution of a threonine to isoleucine at position 315 of ABL) which is situated in the 
middle of the ATP-binding cleft. 
[30,31]
 T315I mutation eliminates the crucial hydrogen-
bonding interaction required for high-affinity Imatinib-binding and the bulky isoleucine side-
chain emerges into the catalytic ATP-binding pocket, sterically hindering inhibitor binding, 
thereby providing an explanation for its drug resistance (Figure 1.8).
 [32] 
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Figure-1.8: Imatinib resistance. Mutation of the gatekeeper residue to isoleucine introduces resistance (T315I 
mutation). [11] 
 
1.7. Second Generation ATP-Competitive BCR-ABL Inhibitors  
 
The emergence of resistance to Imatinib through BCR-ABL-dependent mechanisms such as 
kinase domain mutations, spurred the development of the second generation tyrosine kinase 
inhibitors (TKIs); 
[33]
 Nilotinib, Dasatinib and Bosutinib (Table-1.1). 
[9] 
 
Table 1.1: List of first and second generation of BCR-ABL tyrosine kinase inhibitors 
 
Compound Description Structure 
First generation BCR ABL kinase inhibitors 
 
Imatinib 
 
BCR-ABL 
 
N
N
N
N
H
N
H
O
N
N
 
Second generation BCR ABL kinase inhibitors 
 
Nilotinib 
 
BCR-ABL 
N
N
N
HN
O
NH
N
F
F
F
N
 
 
Dasatinib 
 
BCR-ABL Cl
NH
O
N
S N
H
N
N
N
N OH
 
 
Bosutinib 
 
BCR-ABL 
N
O
O
NN
HN
CN O
Cl
Cl
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Nilotinib, like Imatinib, recognizes and binds the inactive “DFG- out” conformation of the 
ABL kinase. 
[34, 35] 
 Dasatinib inhibits both the active and inactive conformations of the kinase 
domain and has a much broader specificity profile, with activity against SRC kinases, c-KIT, 
PDGFR, ABL and many others. 
[33] 
Dasatinib overcomes most Imatinib resistant mutations 
with the exception of T315I. 
[36]
 Although both compounds inhibit most of the mutations that 
induce resistance to Imatinib, neither compound is capable of inhibiting the “gatekeeper” 
T315I mutation. Both Dasatinib and Nilotinib make a hydrogen bonding interaction to the 
side-chain hydroxyl group of T315I, and their binding modes are incompatible with 
introduction of a large isobutyl side chain of isoleucine. 
[37, 38] 
Bosutinib has dual SRC/ABL 
tyrosine kinase inhibitory activity, but no significant activity against c-KIT and PDGFR. This 
compound also decreases the phosphorylation of many downstream cellular proteins including 
MAPKs, STAT5 and others and inhibits proliferation of CML cells. Bosutinib showed in vitro 
activity against all Imatinib resistant mutants except T315I. 
[17]  
 
The T315I mutation is the most resistant to inhibition because of a combination of several 
factors, including steric hindrance of drug binding, loss of a key hydrogen-bonding interaction 
with the T315 side chain hydroxyl group exploited by Imatinib, Nilotinib and Dasatinib and 
potentially through increasing aberrant intrinsic kinase activity accompanied by aberrant 
substrate phosphorylation. 
[39]
 
 
1.8. Other BCR-ABL tyrosine kinase inhibitors 
 
The clinical importance of the gatekeeper mutation T315I led to synthesis of novel inhibitors 
that are able to circumvent this mutation. 
[40]
 Several compounds targeting T315I are being 
developed, which are more potent and/or are active against the emerging Gleevec resistant 
BCR-ABL clones in treated patients and may overcome resistance. Some of these inhibitors 
with their structures and description are shown in table 1.2-a & b. 
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Table 1.2-a: List of BCR-ABL tyrosine kinase inhibitors 
 
Compound Description Structure 
 
AP23464 
A dual SRC/ABL inhibitors and exhibits 
only moderate potency toward T315I 
BCR-ABL. 
NN
N
N
N
HHO
P
O
 
 
 
 
PD180970 
Inhibits Bcr/Abl tyrosine phosphorylation 
at an IC50 of 170 nM  
It  also has activity against Imatinib 
mesylate–resistant K562 cells and Ba/F3-
P210 cells expressing BCR/ABL kinase 
domain mutations found in patients with 
CML resistant to imatinib mesylate. [41] 
 
N
N NN
H
O
F
Cl
Cl
 
 
 
 
 
HG-7-85-01 
- A ‘hybrid design’ between Dasatinib and 
the Nilotinib, and is capable of inhibiting 
T315I BCR- ABL 
- It has the ability to potently inhibit 
kinases that possess either a threonine or a 
larger hydrophobic residue, such as 
isoleucine, methionine, or phenylalanine. 
[42] 
 
 
O
NH
N
SHN
O
N N
CF3
 
 
 
AP24163 
Dual SRC/ABL inhibitors and exhibits 
only moderate potency toward T315I 
BCR-ABL. AP24163 inhibits the 
gatekeeper mutant of BCR-ABL by 
employing both mechanisms by disrupting 
the hydrophobic spine and by constraining 
the flexibility of P-loop. [43] 
 
N
HN
O
N
N
N
N
NHN
F
F
F
 
 
 
Compound 14  
A ‘hybrid design’ between PD166326 and 
Imatinib, disrupts the assembly of the 
hydrophobic spine, thereby locking the 
kinase in an inactive 'DFG-out' 
conformation. [44] 
 
N
N N
N
H2N O
N
H
O
F
F
F
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Table 1.2-b: List of BCR-ABL tyrosine kinase inhibitors 
 
Compound Description Structure 
 
 
Ponatinib 
ABL/SRC inhibitor which has demonstrated 
activity against all tested mutants that are 
resistant to Imatinib, including T315I. [45] 
N
N
N
O
N
H
N
N
F
F
F
 
 
 
PD166326 
It has the ability to bind the BCR/ABL 
kinase domain in either the active or inactive 
conformation. PD166326, have activity 
against many of the most prevalent Imatinib 
resistant except for P210 T315I. [46] 
 
 
N
NN
H
O
Cl
Cl
HO
 
 
 
SGX393 
A potent inhibitor of native and T315I-
mutant BCR-ABL kinase. SGX393 
suppresses outgrowth of all BCR-ABL 
escape mutants when combined with 
Nilotinib or Dasatinib.[47] 
 
 
Not published yet  
 
 
 
PHA-739358 
A pan–Aurora kinase inhibitor with activity 
against T315 BCR-ABL kinase. PHA- 
739358 binds to the active conformation of 
the mutant kinase in a mode that 
accommodates the substitution of isoleucine 
for threonine, thus avoiding steric clash. [9] 
 
N
NH
O
N
HN N
N
O
O
 
 
 
 
 
Compound 4 
One of the series of the alkyne containing 
type II inhibitors that can circumvent the 
T315I BCR-ABL “gatekeeper” mutation by 
bridging the ATP and allosteric binding site 
using a linker segment that can accommodate 
a larger gatekeeper residue. [48] 
 
O
H
N
N
H
O
N
N
F
F
F
 
 
 
 
DCC-2036 
- The binding, DCC-2036 to ABL or 
ABL/T315I induces and stabilizes the “DFG-
out”, catalytically inactive conformation of 
the kinase domain, precluding 
phosphorylation of activation loop residue 
Y393 and a critical event preceding full 
catalytic activation of ABL kinase. [49] 
 
N
N
N
N
H
N
H
O
N
N
HO
O
F
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1.9 Non-ATP-competitive inhibitors of BCR-ABL 
 
A potential alternative approach to ATP-competitive BCR-ABL inhibition is to use molecules 
that inhibit the kinase activity by non-ATP competitive inhibitors which are divided into two 
types: 1) Allosteric mechanism. 2) Substrate competitor inhibitors. This strategy has the 
advantage that the Imatinib-resistant mutants are unlikely to be resistant to such inhibitors, 
owing to the different binding sites. In addition non-ATP competitive kinase inhibitors can be 
highly selective for a particular kinase because they can exploit non-conserved kinase 
regulatory mechanisms. 
Myristoyl binding pocket (MBP) was reported few years ago as an allosteric site and a 
potential drug target. 
[50]
 ABL tyrosine kinase has an N-terminal ‘‘Cap’’ that is implicated in 
regulating the autophosphorylation activity of the ABL kinase. 
[51]
 The N-terminus of c-ABL 
is myristoylated, this N-myrisotyl moiety blocks the activity of ABL as it binds to a 
hydrophobic pocket (Myristoyl Binding Pocket - MBP) located in the C lobe of the c-ABL 
kinase domain (Figure 1.9). 
[52] 
 
 
Figure-1.9: Schematic diagram showing the domain structures of c-ABL1b, and BCR-ABL [52]. 
 
When the N-terminus myristate binds to the hydrophobic pocket it induces a conformational 
changes that enable intra-molecular docking of the SH2 domain to the kinase domain through 
an interlocking network of hydrogen bonding interactions 
[50]
 thereby enforcing an auto-
inhibited conformation, a process termed “Capping”. This internal docking requires the 
induction of a sharp bend in the C-terminal helix at the base of the kinase domain. 
[37]
 
Therefore the lack of the amino-terminal auto-inhibitory region of ABL in the BCR-ABL 
fusion protein might play a role in the activation of BCR-ABL (Figure-1.10). 
[52] 
In the context 
of the t(9;22), the N-terminal auto-inhibitory “Cap” region is substituted by the BCR portion 
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of the fusion protein. The absence of the “Cap” region allows the BCR-ABL to “escape” auto-
inhibition contributing to the constitutive activation of its kinase activity. 
[49] 
 
 
 
 
 
 
 
 
 
 
Figure-1.10: The inhibition of the ABL-kinase activity by “capping” [52] 
 
Interestingly, small molecules that mimic the interaction of the cap myristoyl group with the 
C-lobe are also effective c-ABL kinase inhibitors, suggesting that the myristic-acid-binding 
pocket is a unique feature that allosterically controls the kinase active site. 
[52]
 High throughput 
screening for inhibitors of BCR-ABL dependent cell proliferation resulted in the identification 
of a lead compound that was subsequently modified to give (GNF-2) 
[50] 
as a selective non-
ATP competitive inhibitor of cellular BCR-ABL kinase activity that targets the myristate 
binding site. 
[53] 
A co-crystal structure showed that binding of GNF-2 to the myristate pocket 
induces a bent conformational of I helix that stabilizes the autoinhibited form of ABL. The 
conformations of the myristate and GNF-2 complexes are comparable to each other. In 
addition, GNF-2 was shown to inhibit the kinase activity of non-myristoylated c-ABL more 
potently than that of myristoylated c-ABL by binding to the myristate-binding pocket in the C-
lobe of the kinase domain. 
[54]
 As expected, most of the interactions between GNF-2 and the 
protein are hydrophobic. 
[55]
 
 
Mutations of three residues near the mouth of the myristate-binding site (C464Y, P465S and 
E505K) were reported to cause complete resistance to the binding of GNF-2, presumably for 
steric reasons (Figure-1.11, Table 1.3). 
[55] 
GNF-2 could inhibit the phosphorylation of Bcr–
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ABL and STAT5 in all mutants except the three mentioned myristate-site mutations and the 
‘gatekeeper’ T315I mutation. The myristate-site mutations directly interfere with drug 
binding, whereas the non-myristate-site mutants function through a different mechanism, 
which may involve disfavoring the inhibited conformation induced after binding of GNF-2.  
 
 
 
 
 
 
 
Figure-1.11: Location of BCR–ABL GNF-2 resistance mutations. Mutations indicated by red spheres on ABL 
with size proportional to the degree of resistance. [56] 
Table-1.3: IC50 for growth inhibition by Imatinib or GNF-2 for wild-type and mutant BCR–ABL transformed 
Ba/F3 cells. The numbers of colonies that emerged after 12 days in the presence of 20 µM GNF-2 are indicated. 
[56] 
 
 
 
 
 
 
 
 
IC50 (M) 
Mutation 
Imatinib GNF-2 
No. of 
Resistant 
colonies 
Bcr–ABL 0.48 0.26 0 
T315l 10.0 10.0 24 
P112S 0.64 5.28 13 
Y128D 0.40 4.07 19 
Y139C 0.41 2.22 14 
S229P 0.85 6.06 19 
C464Y 0.30 10.0 24 
P465S 0.24 10.0 24 
F497L 0.13 1.93 1 
E505K 0.24 10.0 24 
V506L 0.23 1.25 11 
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A recent study showed that Dasatinib is capable of cooperating with GNF-2 in inhibiting the 
proliferation of Ba/F3 cells carrying the native or the T315I mutated BCR-ABL, whereas no 
cooperation was observed between GNF-2 and (Imatinib and Nilotinib) in controlling the 
proliferation and colonogenicity of the parental Ba/F3 cells. Indeed, the cooperation with 
Dasatinib was more potent than the one observed with Imatinib or Nilotinib. Presence of 1 M 
of the ABL kinase inhibitors reduced the IC50 of GNF-2 from 25 M to 10.5 M, 13 M, and 
3.5 M when Imatinib, Nilotinib and Dasatinib were used, respectively (Table-1.4). 
[56]
 The 
enhanced activity of the combination of GNF-2 with Dasatinib might be due to the inhibitory 
activity of Dasatinib on SRC kinase which is involved in STAT5 phosphorylation, 
[56]
 in 
addition that GNF-2 introduces changes in the overall conformations of BCR/ABL-T315I, 
which renders the ATP-binding site more accessible to Dasatinib. 
[49]   
Table-1.4: Cooperation between GNF-2 and AKIs in colonogenicity inhibition of Ba/F3 p185 BCR-ABL T315I 
cells. [56] 
 AKIs IC50(µM) 
GNF-2  25 ± 0.707 
GNF-2 Imatinib (0.1µM) 14.8 ± 3.535 
GNF-2 Nilotinib (0.1µM) 16.5 ± 1.606 
GNF-2 Dasatinib (0.1µM) 13 ± 1.414 
GNF-2 Imatinib (1µM) 10.5 ± 0.707 
GNF-2 Nilotinib (1µM) 13 ± 3.535 
GNF-2 Dasatinib (1µM) 3.3 ± 0.354 
 
GNF-2 presents an intriguing lead molecule for the design of allosteric inhibitors of BCR-
ABL, which could conceivably inhibit the activity of Imatinib-resistant BCR-ABL kinase-
domain mutants. 
[50] 
GNF-5, an analogue of GNF-2 possessing similar cellular BCR–ABL 
inhibitory activity but having more favorable pharmacokinetic properties, 
[55] 
is capable of 
synergizing with ATP-competitive inhibitors such as Nilotinib to inhibit the proliferation of 
T315I BCR-ABL (Figure 1.12). One possible explanation for the cooperative effect of GNF-5 
and Nilotinib is that GNF-5 binding to the myristate pocket can cause dynamic perturbations 
to residues in the ATP-binding site (conformational changes) and provides a mechanism by 
which synergistic interactions between these two sites could occur and stabilizes the inactive 
form of the T315I mutant. 
[55]
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Figure-1.12: Cellular and enzymatic inhibition of wild-type and mutants by combination treatments. IC50 for 
inhibition of wild-type, E505K and T315I ABL kinase activity by GNF-5, Nilotinib or a combination of the two 
at an ATP concentration of 20 µM. [55]  
 
More novel compounds have been developed that can effectively target the BCR-ABL 
myristate binding site, but as expected, all the compounds are inactive on T315I mutant and 
the myristate-binding-site mutant E505K. Some of these analogues with 5- to 10-fold 
improved against wild-type and some BCR-ABL mutants such as E255K relative to GNF-2 
(Table-1.5). 
[53] 
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Table-1.5: BCR-ABL Structure–Activity Relationships for 4,6-Disubstituted Pyrimidines [53] 
 
Structure Compound code Ba/F3
a
 BCR-ABL
b
 
O
F
F
F
N
H
NN O
NH2
 
 
GNF-2 (1) 
 
>10 
 
0.14 
O
F
F
F
N
H
NN O
N
H
OH
 
 
GNF-5 (2) 
 
>10 
 
0.43 
O
F
F
F
NH
N
N S
NH2
O
O
 
 
5g 
 
>10 
 
0.12 
O
F
F
F
NH
N
N NHSO2Me 
 
5h 
 
2.21 
 
0.04 
O
F
F
F
NH
N
N
NH
N
 
 
6a 
 
>10 
 
0.09 
O
F
F
F
NH
N
N S
O
N
N
 
 
14d 
 
2.69 
 
0.048 
O
H
N
F
F
F
N
N
N
N
 
21j 7.3 0.16 
O NH
F
F
F
N
N
N
N
N
 
 
21k 
 
>10 
 
2.96 
O NH
F
F
F
N
N
N
N
S
N  
 
21l 
 
>10 
 
6.92 
a Cytotoxicity (EC50, µM) on parental Ba/F3. 
b Antiproliferative activity (EC50, µM) on wt BCR-ABL-Ba/F3 
 
Another regulatory site of the BCR-ABL kinase is the substrate-binding sites (Figure 1.13). 
ON012380 compound interacts with this site, perhaps through a covalent interaction, and 
exhibits low nanomolar activity against Imatinib-resistant BCR–ABL mutants, including 
T315I. 
[18]
 ON012380 showed a 10-fold stronger inhibition of wild-type BCR–ABL compared 
with Imatinib. It inhibits the growth of cells expressing the wild-type BCR–ABL protein and 
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all of the Imatinib-resistant kinase domain mutations, even T315I, at a concentration of less 
than 10 nM. ON012380 also works synergistically with Imatinib to inhibit wild-type BCR–
ABL. 
[57] 
 
 
 
 
 
 
 
 
 
Figure-1.13: GNF-2, Imatinib and ON012380 binding to different binding sites in the kinase domain. [58] 
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Aim of this work:  
 
In the current work we aim to explore the idea of targeting leukemia cancer cells with novel 
molecular entities that bind selectively and in high specificity to the hydrophobic pocket of the 
Abl kinase, where a myristoyl tail with a long hydrocarbon chain scaffold is bound in the auto-
regulating process of wild type Abl, but is missing in the oncoprotein Bcr-Abl product. Since 
myristate being still the only known inhibitor, we have launched an investigation to explore 
the possibility of modifying the myristoyl scaffold in order to produce potential new binders 
that could exploit interactions with side chains and main chain of the MBP. We demonstrate 
the combination of modeling, synthesis and biological experiments that have led to the 
discovery of mainly novel inhibitors that are based on the myristoyl scaffold. 
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Chapter Two: Results and Discussion 
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2. Results and Discussion  
 
The recently published crystal structures of c-ABL with the N-myristoyl moiety form the basis 
for computerized structure based drug design methods, 
[50]
 which enabled Dr. Amiram 
Goldblum’s lab at the Hebrew University to propose sets of candidate derivatives of myristate 
that could provide effective inhibitors of BCR-ABL by targeting the MBP in the oncoprotein 
with high affinity. * Series of myristate mimics were synthesized and screened in biochemical 
and biological relevant assays. They are functionally evaluated for their potency to inhibit the 
auto-phosphorylation in Ba/F3 BCR-ABL transfected cells carrying either the native or the 
T315I mutated form.  
 
2.1 Synthetic Chemistry 
 
The synthesized compounds were divided into two main groups: I) aromatic myristate 
analogues and II) aromatic–amide myristate analogues (Figure-2.1). Two different synthetic 
methodologies were used to achieve the sketched structures. 
X
R1
O
N
H
X
OO
R
R1
O
OH
Myristic Acid
R = -CF3, Ethyl, Ph-, Cl, I.
X= O, R1= Ehyl
X= NH, R1= propyl
Group (I): aromatic 
myristate analogues
Group (II): aromatic- 
amide-myristate 
analogues
 
Figure-2.1: Rational for developing the aromatic-myristate analogues 
* Personal interview with Dr. Amiram Goldblum at the Hebrew University 
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2.1.1 Synthesis of aromatic myristate analogues (Group (I)):  
 
The first subgroup of compounds we started to synthesize was the aromatic containing 
myristate derivatives. Such subgroup could be categorized according to the position of the 
aromatic moiety along the carbon skeleton a) those with aromatic ring (including phenyl and 
naphthyl derivatives) at the -terminus (Figure-2.2. A), b) with aromatic ring inserted in 
between the carbon backbone (Figure-2.2. B) and the naphthyl derivatives (Figure-2.2. C).  
O
OH
O
OH
A B
Myrsitic Acid
OH
O
OH
O
C
 
Figure-2.2: Aromatic myristate sub-categories: (A) aromatic ring at the -terminus, (B) aromatic ring along the 
backbone, (C) the naphthyl derivatives. 
 
The aromatic myristate sub-categories (A, B and C) were synthesized using the Wittig 
olefination methodology where triphenylphosphonium ylide of the carboxy protected alkyl 
halide is combined with the corresponding aldehyde under strong basic conditions. 
 
2.1.1.1 Synthesis of Subgroups A & B: Phenyl-myristate analogues 
 
Synthesis of this group was starting with the commercially available n-bromoalkanoic acids 
(8-bromooctanoic (1) and 10-bromodecanoic (2)) in a multistep process as shown in scheme 
2.1. Reaction progress was monitored using TLC in all steps. Scheme-2.1 describes the 
synthesis of (9-(4-ethylphenyl)-non-8-enoic acid Z-(18), and E-(19), 9-(4-nitrophenyl)-non-8-
enoic acid Z-(20) and E-(21), 11-phenylundecenoic acid (22, 23) via conversion of the n-
bromoalkanoic acids (1, 2) to the corresponding ethyl esters (4,5) in refluxing acidic ethanol 
(or methanol in case of (3)). The n-bromoalkanoic acid ethyl esters (8-bromooctanoic acid 
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methyl ester (3), 8-bromoctanoic acid ethyl ester (4), or 10-bromodecanoic acid ethyl ester (5) 
were transformed to the triphenylphosphonium bromide salts [(9-ethoxycarbonylnonyl)-
triphenylphosphonium bromide (6), (7-ethoxycarbonylheptyl)-triphenylphosphonium bromide 
(7), (7-methoxycarbonylheptyl)-triphenylphosphonium bromide (8)] by continuous refluxing 
in dry dioxane with a slight excess of triphenylphosphine (TPP). The preparation of the 
phosphonium intermediate was laborious and demanded very long time of refluxing in high 
boiling solvents. 
 
a) b)
(CH2)x
O
OH
Br
x = 6 (1)
x = 8 (2)
(CH2)x
O
O
Br
R'
(CH2)x
O
O
Br
R'
P
PhPh
Ph
O
H
(CH2)x
O O
R'
R
R
x = 6, R = -CH2CH3,R'= -CH3, 
Z- (12), E- (13) 
x = 6, R = -NO2, R'=-CH3,  
Z- (14), E- (15) 
x= 8,  R = H, R'= -CH2CH3, 
Z- (16), E- (17)
(CH2)x
O OH
R
(CH2)x
O
H
N
R
R = H (9), -NO2 (10), -CH2CH3 
(11)
x = 6 (3), R'=-CH3
x = 6 (4), R'= -CH2CH3
x = 8 (5), R'= -CH2CH3
x = 6 (6), R'=-CH3
x = 6 (7), R'= -CH2CH3
x = 8 (8), R'= -CH2CH3
c)
d)
x = 6, R = -CH2CH3, Z- (18), E- (19)
x = 6, R = -NO2,  Z- (20), E- (21) 
x = 8,  R = H, Z- (22), E- (23)
e)
x = 6, R = -CH2CH3,  (24)
x = 8,  R = H, (25)
f)
x = 6, R = -CH2CH3, Z- (26), E- (27)
(18,19)
(CH2)x
O OH
R
 
Scheme-2.1: Synthesis of the aromatic myristate analogues. 
Reagents and conditions: (a) Ethanol / methanol, H +, reflux 12 hrs, evaporation, extraction with ethyl acetate 
against 5%NaHCO3,  drying MgSO4, evaporation; (b) P(Ph)3, dioxane,  reflux 96 hour (c) Dry THF, cooling to  -
78 °C under N2,  n-BuLi (1.6M)   room temperature 1 hr,   -78 ºC, 1.2eq aldehdyde (benzaldehyde (9), p-
nitrobenzaldehyde (10), or ethyl benzaldehyde (11)),   room temperature 3 hrs, washing with 5% NaHCO3, 
evaporation to dryness, column chromatography; (d) 5%NaOH, MeOH-H2O (2:1; v/v), 5 hrs at room 
temperature; 5% HCl, extraction (DCM/H2O) (e) H2(g) Pd-C, 100 psi, 4 hrs; (f) 1.1 equivalent DCC, 1.1 
equivalent NHS, 2 equivalents n-propylamine. 
 
The synthetic strategy used for preparing (12-17) exploited Wittig olefination methodology 
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where triphenylphosphonium ylide of alkanoic ester is fused with the corresponding aldehyde 
(benzaldehyde (9), 4-nitrobenzaldehyde (10), 4-ethylbenzaldehyde (11)) under strong basic 
conditions. The olefination step was tried using different conditions. First we have been trying 
the classical phase transfer conditions using high concentration of 50% aqueous NaOH or 
KOH. This afforded no detectable desired products. Later we also have tried to use different 
concentrations of alkoxides (NaOMe or NaOEt) as bases but this also was not successful. The 
organic base n-butyl lithium (n-BuLi 1.6M) was used, which gave reasonable yields of the 
desired products with additional by-products, which were also detected. However, the n-BuLi 
was not absolutely regioselective and resulted in the formation of high ratio of E- with little 
amount of the Z- isomers.  The reaction was performed in dry THF under inert conditions and 
at -78 °C. After completion of the reaction (as judged by TLC) the product (9-(4-ethylphenyl)-
non-8-enoic acid methyl ester (Z-12, E-13), 9-(4-nitrooxyphenyl)-non-8-enoic acid methyl 
ester (Z-14, E-15), 11-phenylundec-10-enoic acid ethyl ester (Z-16, E-17)) was purified using 
silica gel chromatography in low to modest yields (23%, 20%, 37.5%) respectively. The 
purification of these lipophilic compounds turned to be not easy task especially when trying to 
separate Z- and E-regioisomers. After hydrolysing the methyl or ethyl ester under basic 
conditions (5%NaOH) using and neutralization the aromatic alkenoic acid, (9-(4-ethylphenyl)-
non-8-enoic acid (18, 19), 9-(4-nitrooxyphenyl)-non-8-enoic acid (20, 21), 11-phenylundec-
10-enoic acid (22, 23) were collected. Based on
 1
H-NMR analysis the product (22, 23) was a 
mixture of E- 90% and Z-olefin 10%. 
 
Since the p-nitrobenzaldehyde (10) contains no acidic protons and it is more reactive than 
other aldehydes, the synthesis of compound (20, 21) was a model reaction to help us find the 
conditions that could be generalized to other compounds using similar or modified procedure 
to improve the yield and the regioselectivity. 
 
The aromatic acid compounds (19) and (23) were then reduced to give rise to the saturated 
aromatic alkanoic acids [9-(4-ethylphenyl)-nonanoic acid (24), 11-phenylundecanoic acid 
(25)]. In addition, the unsaturated acids (18,19) were coupled to n-propylamine using standard 
peptide chemistry affording the amide analogues 9-(4-ethylphenyl)-non-8- enoic acid 
propylamide (26,27) respectively.  
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2.1.1.2 Subgroup C: 2-Naphthyl-myristate analogues 
 
The following compounds were prepared to see whether the MBP is wide enough to 
accommodate such fused aromatic system. Naphthyl myristate derivatives (28,29, 30) were 
synthesized using the same methodology used in the synthesis of phenyl-myristate analogues. 
Naphthyl aldehyde was used to react with (7-ethoxycarbonylheptyl)-triphenylphosphonium 
bromide (7) to produce 9-naphthalen-2-yl-non-8-enoic acid ethyl ester (28), which was then 
hydrolyzed under basic condition to afford 9-naphthalen-2-yl-non-8-enoic acid (29). (28) was 
also reduced to the saturated aromatic alkanoic ester 9-naphthalen-2-yl-nonanoic acid ethyl 
ester (30). (Scheme-2.2) 
 
(CH2)x
O O
(CH2)x
O OH
c)
b)
(CH2)x
O O
O
H
a)
(7)
x=6, Z&E-(28)                                                   x=6, Z-(29)
x=6, (30)
 
Scheme-2.2: Synthesis of naphthyl-myristate derivatives. 
Reagents and conditions: (a) Dry THF, cooling to  -78 °C under N2,  n-BuLi (1.6M)   room temperature 1 hr, 
  -78 ºC, 1.0eq naphthaldehyde,   room temperature 3 hrs, washing with 5% NaHCO3, evaporation to 
dryness, column chromatography; (b) 5%NaOH, MeOH-H2O (2:1; v/v), 5 hrs at room temperature; 5% HCl, 
extraction (DCM/H2O); (c) H2(g) Pd-C, 100 psi, 4 hrs. 
 
Based on the assumption that hydrophobic interactions are significant in the binding of 
myristate analogues to MBP 
[55]
, we decided to evaluate the biological activity of olefin 
containing intermediates ester/acids and amides ((12,13), (18,19), (28,29) and (26,27) 
respectively.  
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2.1.2 Synthesis of Aromatic-Amide Myristate analogues (Group (II)): 
 
Since the aromatic ring conjugated to double bond in group (I) have shown improved activity 
compared to myristic acid, we thought that replacing the alkene moiety with amide group 
capable of participating in hydrogen bond system, which would enhance the affinity of 
predicted analogues with the (MBP). To that end a series of aromatic-amidated-myristate 
analogues were synthesized and the biological activity was assessed against BCR-ABL 
positive leukemia cells. 
 
The synthesis of this series of compounds was achieved in three steps process. The first step 
was the electrophilic amination of the corresponding bromoalkanoic acid [1, 2 and 11-
bromoundecanoic acid (31)] using excess of aqueous ammonium hydroxide to afford the 
amine alkanoic acid [8-aminooctanoic acid (32), 10-aminodecanoic acid (33), 11-
aminoundecanoic acid (34)] respectively (Scheme-2.3). Then the carboxyl terminal of the 
amine alkanoic acid was protected with ethyl (or methyl (67)) ester in refluxed alcoholic 
solution under acidic conditions. The hydrochloride ammonium salt of the corresponding ethyl 
esters [8-aminooctanoic acid ethyl ester (35), 10-aminodecanoic acid ethyl ester (36), 11-
aminoundecanoic acid ethyl ester (37)] were purified by crystallization from cold ethanol.   
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a) b)
 
Scheme-2.3: Synthesis of amino-alkanoic acid ethyl esters. 
Reagents and conditions: (a) 5 equivalents NH4OH 25%, 30 hours at room temperature, evaporation to dryness; 
(b) 25ml EtOH, HCl gas at 0°C, reflux, TLC MeOH: CHCl3; 5:95; v/v; I2, evaporation to dryness. 
 
The amino-alkanoic acid ethyl esters were then coupled to aromatic carboxylic acids (38, 41, 
43, 45, 47, 49, 52, 56, 60, 62, 66) using DCC/NHS as a coupling agent to give rise to the 
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aromatic amidated myristate analogues (39, 40, 42, 44, 46, 48, 50, 51, 53, 54, 55, 57,58,59, 61, 
63,64,65, 67) (Scheme 2.4). Compound (44) was also synthesized using benzoic anhydride or 
benzoyl chloride. The overall yields in the three steps ranged between 50% for (44), 91% (37) 
and 100% (34)   
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Scheme-2.4: Synthesis of the aromatic amide-myristate derivatives. 
Reagents and conditions: (a) 5ml DMF, 1.1 TEA, 1.1 DCC, stirring over night at room temperature, TLC 
(CHCl3), evaporation, extraction ethyl acetate /H2O, purification by column chromatography CHCl3: Hexane 
(40:60; v/v). 
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The aromatic amidated-alkanoic acid ethyl ester [11-benzoylaminoundecanoic acid ethyl ester 
(44), 8-(4-trifluoromethyl-benzoylamino)-octanoic acid ethyl ester (53), 8-(4-ethyl-
benzoylamino)-octanoic acid ethyl ester (63)] was then hydrolyzed under basic conditions to 
give the acid form [11-benzoylaminoundecanoic acid (68), 8-(4-trifluoromethyl-
benzoylamino)-octanoic acid (69), 8-(4-ethyl-benzoylamino)-octanoic acid (70)] respectively. 
In addition (68) was coupled to n-propylamine using standard peptide chemistry affording the 
amide analogue [n-(10-propylcarbamoyldecyl)-benzamide (71). 
 
n
(44)
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(68), n=8, R= H
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Scheme-2.5: Synthesis of (68,69,70,71). 
Reagents and conditions: (a) NaOH 5% H2O:EtOH 1:2, heating at 50ºC for 30minutes, TLC 100% CHCl3, 
acidification with HCl, evaporation to dryness, extraction with ethylacetate; (b)  5ml DMF, 1.1eq DCC, 1eq NHS, 
Stirring overnight  at room temperature, TLC 100% CHCl3,  1.1eq propylamine, evaporation, extraction, 
purification by column chromatography [CHCl3: Hexane (40:60; v/v)], recrystallization from ethanol, filtration. 
 
2.2  Biological evaluation: 
 
2.2.1 In vitro Assessment of Cellular Auto-phosphorylation Activity in Ba/F3 BCR-ABL 
cells: 
 
We utilized Ba/F3, murine B lymphocytes cells, transfected with BCR-ABL gene for the  
evaluation of the cellular auto-phosphorylation activity of the different compounds. We 
noticed that responsiveness to allosteric inhibitors such as GNF-2 is a cell-type specific and 
also depends on the size of BCR-ABL. As shown in figure-2.3 while activity of Imatinib was 
comparable against p185 and p210 BCR-ABL, activity of GNF-2 was varied. GNF-2 was less 
effective in inhibiting cellular auto-phosphorylation of Ba/F3 with p210 BCR-ABL compared 
to p185 BCR-ABL. We screened our compounds for inhibitory activity of the p210 BCR-ABL 
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auto-phosphorylation function. Compounds were evaluated in duplicate in three 
concentrations 200µM, 100µM and 50µM. BCR-ABL transfected cells were treated for one 
hour and viability of the cells were determined using Trypan blue exclusion assay and the 
lysates were used to evaluate cellular auto-phosphorylation. 
 
 
Figure-2.3: Auto-phosphorylation inhibition of STAT5 and p185, p210 BCR-ABL by GNF-2. 
 
2.2.2 Toxicity and inhibition of BCR-ABL cellular auto-phosphorylation by MAJY 
compounds 
 
The following compounds (Table 2.1) were synthesized and their biological activities were 
carried out for inhibition of BCR-ABL cellular auto-phosphorylation. 
Table-2.1-a: Codes and structures of the synthesized compounds 
Compound  Compound 
code 
 Structure Compound  Compound 
code 
Structure 
 
 
 
20,21 
 
 
 
MAJY 1 
 
 
 
 
 
18,19 
 
 
 
MAJY 3 
 
 
 
 
 
 
 
 
 
 
 
14,15 
 
 
 
 
 
 
 
MAJY 2 
  
 
 
 
12,13 
 
 
 
 
MAJY 4 
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Table-2.1-b: Codes and structures of the synthesized compounds 
 
Compound  Compound 
code 
 Structure Compound  Compound 
code 
Structure 
 
22,23 
 
 
 
MAJY 11 
 
 
 
53 MAJY 39 


16,17 
 
 
MAJY 12 
 
 
 
70 MAJY 40 
 
 
25 
 
 
MAJY 16 
 
 
63 MAJY 41 
 
 
28 
 
 
 
MAJY 23 
 
 
 
68 MAJY 42 
 
16 
 
MAJY 24 
 
 
 
44 
 
 
MAJY 43 
 


24 
 
MAJY 25 
 
 
 
57 
 
MAJY 45 

 
26, 27 
 
 
 
MAJY 26 
 
 
 
58 MAJY 54 

22 MAJY 27 
 
54 
 
 
MAJY 55 
 

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MAJY 28 
 
 
50 MAJY 56 


30 
 
 
MAJY 31 
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Table-2.1-c: Codes and structures of the synthesized compounds 
 
Compound  Compound 
code 
 Structure Compound  Compound 
code 
Structure 
67 
 
MAJY 65 
 
65 
 
 
MAJY 72 
 
 
61 
 
 
MAJY 67 
 
 
 
71 MAJY 73 
 
51 
 
 
MAJY 68 
 
 
46 MAJY 74 
 
42 
 
 
MAJY 69 
 
 
48 MAJY 75 
 
 
59 
 
 
MAJY 70 
 
 
55 MAJY 76 
 
40 
 
MAJY 71 
 
    
 
The inhibition of BCR-ABL auto-phosphorelation of our compounds at 100 µM was shown in 
(figure 2.4-A, B and C) with comparison to 1 µM Imatinib and 10 µM GNF-2. The cellular 
viability of the treated cells was also followed. The criteria for selections were activity in 
cellular auto-phosphorylation assay with minimal observed cytotoxicity.  .  
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 Figure-2.4-A: Toxicity and inhibition of BCR-ABL cellular auto-phosphorylation by MAJY 
compounds. Percentage of BCR-ABL auto-phosphorylation (blue) and viability inhibition (red). 
 
 
Figure-2.4-B: Toxicity and inhibition of BCR-ABL cellular auto-phosphorylation by MAJY compounds. 
Percentage of BCR-ABL auto-phosphorylation (blue) and viability inhibition (red). 
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Figure-2.4-C: Toxicity and inhibition of BCR-ABL cellular auto-phosphorylation by MAJY compounds. 
Percentage of BCR-ABL auto-phosphorylation (blue) and viability inhibition (red).  
   
2.2.3 Toxicity and inhibition of T315I mutated BCR-ABL cellular auto-phosphorylation 
by MAJY compounds  
 
Compounds that exhibited good activities in the Ba/F3 BCR-ABL cell lines were tested for 
their ability to affect auto-phosphorylation of T315I mutated BCR-ABL form. The results are 
shown in figure-2.5 which demonstrates that the most active compound in inhibiting auto-
phosphorylation of mutated T315I BCR-ABL was MAJY-43. However, presence of MAJY-43 
showed no noticeable toxicity.  
 
Figure-2.5: Toxicity and inhibition of T315I mutated BCR-ABL cellular auto-phosphorylation by MAJY 
compounds. Percentage of BCR-ABL auto-phosphorylation (blue) and viability inhibition (red). 
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MAJY-43 was tested for its ability to affect levels of phosphorylated native, E255K and T315I 
mutated BCR-ABL by immune blotting (Figure-2.6). 
 
Figure-2.6: Inhibition of phosphorylated native, E255K and T315I mutated BCR-ABL by MAJY-43 in compare 
to GNF-2 and Imatinib. 
 
Imatinib at 1µM was active in inhibiting BCR-ABL auto-phosphorylation in Ba/F3 cells 
carrying native BCR-ABL, but failed to do so in cells carrying the T315I and E255K mutate 
BCR-ABL. In contrast, GNF-2 at 25 µM and 50 µM was not effective in inhibiting BCR-ABL 
auto-phosphorylation in all cells tested. Treatment of Ba/F3 cells containing BCR-ABL with 
MAJY-58 caused the complete elimination of BCR-ABL apparently by degradation 
mechanism. MAJY-58 exhibited a dose-dependent effect and exerted its effect in all Ba/F3 
cells tested. In contrast, MAJY-43 treatment inhibits BCR-ABL auto-phosphorylation without 
lowering the levels of BCR-ABL itself. In addition, MAJY-43 exhibited a dose dependent 
effect and it was active in inhibiting auto-phosphorylation of Ba/F3 cells carrying native, 
T315I and E255K mutated forms of BCR-ABL. 
 
2.2.4 Colonigenicity inhibition: 
 
Anchorage-independent growth of cells is a typical characteristic of the tumorigenicity of 
cancer cells in vitro. Different of our compounds were tested for their ability to affect 
colonogenicity of Ba/F3 harboring native and T315I BCR-ABL constructs. Figure-2.7 shows 
that Imatinib at 1 µM was active in inhibiting colonogenicity of Ba/F3 cells carrying native 
BCR-ABL, but not T315I mutated BCR-ABL. Higher Imatinib concentration (10 µM) was 
active in inhibiting colonogenicity of both cell lines. GNF-2 at higher concentration (50 µM) 
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also was active in inhibiting Ba/F3 cells carrying native and T315I mutated BCR-ABL. Our 
compounds showed variable potency in inhibiting Ba/F3 cells carrying BCR-ABL constructs. 
Interestingly, most compounds showed comparable activity against colonogenicity of Ba/F3 
harboring native or T315I BCR-ABL constructs (Figure-2.7: A and B).  
 
                   Figure-2.7-A,B: Colonigenicity Inhibition of Ba/F3 cells carrying the native and T315I mutated 
BCR-ABL constructs by MAJY compounds. 
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                     C. 
 
Figure-2.7-C: Colonigenicity Inhibition of Ba/F3 cells carrying the native and T315I mutated BCR-ABL 
constructs by MAJY 43 at (10, 30, 100 µM) in comparison to 1µM Imatinib. 
 
Results presented in Figure-2.7A and 2.7C demonstrated that MAJY-43 was active in 
inhibiting colonogenicity of both Ba/F3 BCR-ABL and Ba/F3 BCR-ABL T315I with IC50 of 
13 and 28 µM, respectively.  
 
2.3  BCR-ABL Structure-Activity Relationships (SAR) of aromatic myristates: 
 
Cell-based structure-activity relationship is used to guide the optimization and diversification 
of ligands that are capable of binding to the MBP. Set of different aromatic myristate 
analogues has been synthesized and evaluated for their potency to inhibit the auto-
phosphorylation in Ba/F3 BCR-ABL transfected cells carrying either the native or the T315I 
mutated form in comparison to Imatinib and GNF-2.  
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2.3.1 Effect of Aromatic and Aromatic-ene Myristates:  
 
A series of aromatic myristate analogues were predicted to bind the MBP in higher affinity, 
but actually the biological results showed that some of these compounds were inactive as 
much as their intermediates due to their structure feature such as 11-phenylundecanoic acid 
MAJY-16 (25) and its intermediate 11-phenylundec-10-enoic ethyl ester (MAJY-12) (17). 
 
Three major compounds (MAJY-12, -24 and -26), among the phenyl- myristate analogues, 
showed good activity against the inhibition of BCR-ABL auto-phosphorylation. Knowing that, 
the presence of (MAJY-26) (26,27) caused slightly cytotoxicity to the treated cells. MAJY-26 
comprises p-ethylphenyl ring conjugated to double bond on one end and n-propylamide on the 
other. 
  
The myristate mimic (MAJY-16) (25) demonstrated no inhibition activity as a result of 
replacing the three methylenes residing at the -terminal with aromatic ring, while keeping 
identical distance between the two terminals of the resulting fatty acid. However, when a 
double bond was conjugated to the aromatic ring (MAJY-12) (17) an improved activity was 
observed. While, when the double bond was shifted to two methylenes from the aromatic ring 
(MAJY-4) (12,13) the activity drops.  
 
 
Figure-2.8: Inhibitory effect of aromatic myristate analogues on inhibiting auto-phosphorylation of 
Ba/F3 p210 BCR-ABL. 
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11-phenylundec-10-enoic ethyl ester (MAJY-12) (17) exhibits a partial effect on inhibiting  
auto-phosphorylation of Ba/F3 p210 BCR-ABL [54% vs. at 100 µM], which is not seen in the 
presence of 11-phenylundecanoic acid (MAJY-16) (25) derivatives, this indicates that the 
aromatic moiety at the -terminal of the alkanoic acid is not sufficient by itself to improve the 
activity of the myristate, however, when the aromatic moiety was conjugated to the olefin 
there was improvement in the activity, indicating that additional lipophilic interaction with the 
MBP is a contributor to improved activity. When the aromatic moiety was shifted two 
methylenes toward the amidated carboxy terminal (MAJY-26), the activity at 100 µM was 
improved by 50% and was comparable to Imatinib at 1 µM. Worth to note that at these 
conditions both (MAJY-12, -24 and -26) were much more efficient in inhibiting the auto-
phosphorylation of BCR-ABL than the newly reported allosteric inhibitor GNF-2 at 10 µM. 
Whereas GNF-2 showed more effect on inhibiting auto-phosphorylation of T315I mutated 
BCR-ABL form than (MAJY-12 and -26) do. 
 
Moreover, we thought that increasing the hydrophobicity of MAJY’s compounds by using the 
naphthyl derivatives conjugated to the double bond (MAJY-23 and -28) would increase the 
hydrophobic interactions in the binding to MBP. But indeed, no activity was shown as 
expected against the auto-phosphorylation of Ba/F3 p210 BCR-ABL. 
 
2.3.2 Effect of substitution and chain length of the aromatic-amide myristates: 
 
After the identification of MAJY-12 (17) and -26 (26,27) as two lead compounds with partial 
inhibitory effect of BCR-ABL expressing Ba/F3 cells, set of MAJY-12 (17) analogues were 
prepared but with replacement of the alkene moiety with amide group and keeping the overall 
structural features including the distance between the aromatic moiety and the carboxyl. We 
thought that the insertion the amide group to MAJY-12 (17) would be capable of participating 
in hydrogen bond system, which would enhance the affinity of predicted analogues with the 
(MBP).[MAJY-12 (17)  MAJY-43 (44)].  
 
Several aromatic- amide myristates analogues with different substituent on the aromatic ring 
were synthesized and evaluated on their activity to inhibit BCR-ABL auto-phosphorylation in 
40 
 
Ba/F3 cells. MAJY-43 was the most active compound among all the synthesized compounds 
in this work; MAJY-43 (44) was comparable to that of MAJY-12 (17). We thought by keeping 
the chain length between the carboxy and the aromatic ring constant similar to MAJY-43 with 
changing the substituent this might improve the activity. This includes 4-iodobenzoyl MAJY-
71 (40), 3,4-dimethoxybenzoyl- MAJY-69 (42), 4-fluorophenylacetyl- MAJY-74 (46), 4-(4-
Fluoro-phenyl)-4-oxobutyryl- MAJY-75 (48), 1-naphthoyl- MAJY-68 (51), 4-
Trifluoromethylbenzoyl- MAJY-76 (55), 3-chlorobenzoyl MAJY-70 (59), 4-
biphenylcarbonyl- MAJY-67 (61) and 4-ethylbenzoyl- MAJY-72 (65). The second trial was 
shortening the chain length by one methylene [MAJY-63 (39), -56 (50), -55 (54), -54 (58), -61 
(64), and -65 (67)]. In another trial the chain length was shortened by three methylenes 
[MAJY-39 (53), -45 (57) and -41 (63)]. None of these compounds showed the inhibitory 
potency that [MAJY-12 (17), -26 (26), or -43 (44)] did. The only derivative endowed with 
comparable potency was MAJY-72 (65), in which the aromatic ring is adjacent to the amide 
with an ethyl group at para position with a chain length of ten methylenes separating the 
amide terminus. The three compounds MAJY-12 (17), -43 (44) or -72 (65) have the same 
length of the methylene chain between the carboxy terminal to the aromatic ring that is ten, 
while in MAJY-26 (26) there are eight methylenes. Besides, all active compounds have a 
double bond or amide group adjacent to aromatic moiety.  
 
We expected that increasing the lipophilicity by using large aromatic entities compounds 
MAJY-67 (61) and -68 (51) would increase the activity more than MAJY-43 does, but 
unfortunately such compounds were devoid of activity, this might indicate about the tightness 
of the MBP. On the other hand, activity drops when the aromatic ring was 4-iodinated (40), 3-
chlorinated (59), or when trifluoromethyl resides at p-position at the phenyl (55). In addition, 
shifting the aromatic moiety by single methylene e.g. MAJY-74 (46) or four atoms e.g. 
MAJY-75 (48) also did not enhance the activity.  
 
2.3.3 Effect of Carboxyl Terminal Modification on inhibiting the BCR-ABL auto-
phosphorylation activity: 
 
Some modifications were carried out at the carboxyl terminal of MAJY-12 and -43 (ester, acid 
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and amide) and were also assessed to see its effect on inhibiting the BCR-ABL auto-
phosphorylation activity. While keeping the chain length between the carboxyl terminal and 
the aromatic ring in MAJY-43 (44), the ester carboxyl terminal was hydrolyzed and them 
amidated to afford MAJY-42 (68) and MAJY-73 (71) respectively. MAJY-43 (44) was the 
most active compound in inhibiting the auto-phosphorylation of Ba/F3 p210 BCR-ABL, while 
its acid form MAJY-42 (68) didn’t show any inhibitory effect and the amidated carboxy 
terminal MAJY-73 (71) had about 18% inhibitory effect underlying the role of the amide 
functional group as compared to the acid form (Figure-2.4 B and C).  
 
The activity of inhibiting the BCR-ABL auto-phosphorylation is affected by modifying the 
carboxy terminal (ester, carboxylate, amide) MAJY-4, -3, and -26 respectively as shown in 
Figure-2.9. While keeping the length between the carboxyl terminal and the -methyl, the 
aromatic ring was displaced by two methylenes toward the carboxyl terminal to give rise to 
the ester form MAJY-4 (12,13) and the acid form MAJY-3 (18,19). Both compounds exert 
decreased auto-phosphorylation inhibitory effect when compared to GNF-2 or Imatinib. 
Whereas, the ester form MAJY-26 (26,27) - that has 4-ethyphenyl moiety conjugated to a 
double bond at the -terminal and n-propyl amide at the carboxy terminal- was obtained with 
improved inhibitory activity.   
 
 
Figure-2.9: The effect of the modifying the carboxy terminal (ester, carboxylate, amide) on the activity Gleevec: 
1 µM, GNF-2: 50 µM, MAJYs (3, 4, 25, 26: 100 µM for 1 hr). 
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Compared to MAJY-26 (26,27) which inhibited 78% of the activity BCR-ABL auto-
phosphorylation, however, MAJY-4 (12,13) had 20% inhibitory effect underlying the role of 
the amide functional group as compared to the ester. Both acid forms (18) and (19) were less 
effective than the ester (12,13) and the amide (26,27). Nonetheless, all myristate analogues 
(MAJYs at 100 µM) were more effective in inhibiting the auto-phosphorylation of BCR-ABL-
210 (WT) in BaF3 than did GNF-2 (50 µM). 
 
In the case of MAJY-3 (18,19) and its analogues the ester exerts comparable activity to the 
free carboxylate derivative MAJY-4 (12,13); however the activity drops to half when the 
double bond was reduced in case of free carboxylate analogue MAJY-25 (24). When the 
carbonyl terminal was amidated with n-propylamine in MAJY-26 (26) an approximate 
fourfold increase in the activity was observed. Indicating that the combination of an aromatic 
ring conjugate to a double bond positioned six methylenes from a terminal amide has a 
potentiating effect on the auto-phosphorylation inhibition.  
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Chapter Three: Conclusion 
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3. Conclusion 
 
This research constitutes a new potential approach to the treatment of CML and could become 
complementary to the current method of cure by ATP competitors (Imatinib, Dasatinib, 
Nilotinib, and others). The BCR-ABL inhibitor Imatinib is now the first-choice treatment for 
all newly diagnosed CML patients, but the initial striking efficacy of this drug has been 
overshadowed by the development of clinical resistance. Resistance is mostly caused by the 
acquisition of point mutations in BCR/ABL. The “gatekeeper” mutation T315I confers 
resistance against all available molecular therapy approaches. 
 
Allosteric inhibition represents a promising new strategy for the design of kinase inhibitors 
with improved selectivity and utility in overcoming drug resistance. On chemical biology, this 
research produces new molecular entities that could be useful for studying several 
biomolecular systems in which myristoyl binding pocket exist.  
 
We have presented sets of candidate derivatives of myristate that could provide effective 
inhibitors of BCR-ABL by targeting the myristate binding pocket (MBP) in the BCR-ABL 
oncoprotein. We have shown the ability of different myristate analogues at 100 µM to inhibit 
the auto-phosphorylation in Ba/F3 BCR-ABL transfected cells carrying either the native or the 
T315I mutated form in comparison to 1 µM Imatinib and 10 µM GNF-2. Four major novel 
compounds (MAJY-12, -26, -43 and -72) displayed improved inhibitory potency against the 
auto-phosphorylation of BCR-ABL. The most potent compound was discovered is MAJY-43 
(44), which exhibited a dose dependent effect and it was active in inhibiting auto-
phosphorylation of Ba/F3 cells carrying native, T315I and E255K mutated forms of BCR-
ABL.  
 
We thought that replacing the double bond which increases the lipophilicity in MAJY-12 (17) 
by the amide group MAJY-43 (44) - while keeping the distance between the aromatic moiety 
and the carboxyl terminal constant – is  capable of participating in hydrogen bond system, 
might enhanced the affinity with the (MBP). Whereas using different substituent on the phenyl 
ring didn’t improve the inhibitory potency against the auto-phosphorylation of BCR-ABL in 
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comparison to MAJY-43 (44). The chain length between the aromatic moieties to the carboxyl 
terminal didn’t show that much effect in the inhibitory activity of some compounds. On the 
other hand, the carboxyl terminal has high effect in inhibiting the auto-phosphorylation of 
Ba/F3 p210 BCR-ABL in the case of MAJY-26, -43 and their derivatives. MAJY-43 was also 
active in inhibiting colonogenicity of both Ba/F3 BCR-ABL and Ba/F3 BCR-ABL T315I with 
IC50 of 13 and 28 µM, respectively.  
 
In summary, the in vitro data strongly suggest that a variety of promising lead compounds 
have been identified and found to bind potently to the MBP and inhibit BCR-ABL activity.  
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Chapter Four: Experimental Part 
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4.1. Materials: 
 
Chemicals: triphenylphosphine (PPh3), n-butyl lithium (1.6M) (n-BuLi), benzaldehyde, 
naphthalene-2-carbaldehyde, 11-bromoundecanoic acid, 10-bromodecanoic acid, 8-
bromooctanoic acid, 4-iodobenzoic acid, benzoic anhydride, propyl amine, 3,4-
dimethoxybenzoic acid, (4-fluorophenyl)-acetic acid, 4-(4-fluorophenyl)-4-oxobutanoic acid, 
1-naphthoic acid, 4-trifluoromethylbenzoic acid, 3-chlorobenzoic acid, biphenyl-4-carboxylic 
acid, 4-ethylbenzoic acid, N-carbethoxy phthalimide, 2-iodobenzoic acid, 6-
methoxybenzofuran-2-carboxylic acid, acetic anhydride, 4-aminobenzoic acid, 
tetrachlorophthalic anhydride, dicyclohexylcarbodiimide (DCC), N-hydroxysuucinimide 
(NHS), sodium sulfate (Na2SO4), dimethylformamimde (DMF), dichloromethane (DCM), 
ethyl acetate (Eth. Ac.), triethylamine (TEA), methanol (MeOH), ethanol (EtOH), hexane, 
chloroform (CHCl3) and pyridine were purchased from ACROS Chemicals Ltd. Potassium 
iodide (KI), ammonium hydroxide (NH4OH 25%), sodium hydroxide (NaOH), 
tetrahydrofuran (THF), dioxane and sulfuric acid (H2SO4) were purchased from Aldrich 
Chemicals Ltd. and were used without further purification. Silica gel (Silica gel 60 (0.040-
0.063 mm)), thin layer chromatography (TLC Silica gel 60 F254) sheets were all purchased 
from Merck Ltd.  
Deuterated solvents: D2O, CDCl3 (Chloroform-d), DMSO-d6 (Deuterated dimethyl sulfoxide 
(d6)) was purchased from ACROS Chemicals Ltd.  
1
H-NMR and 
13
C-NMR:  
Data were collected using Varian Unity Inova 500 MHz spectrometer equipped with a 5-mm 
switchable and data were processed using the VNMR software. 
 
4.2. Synthesis and characterization of group (I) myristate analogues:  
 
4.2.1. Synthesis of 11-phenylundec-10-enoic acid ethyl ester (MAJY-12) (16,17): 
 
Step (A): 10-bromodecanoic acid ethyl ester (5). 
10-bromodecanoic (2) (5g, 39.8mmol) were dissolved in ethanol 12ml (398mmol) and 25 ml 
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of toluene and 10 drops of H2SO4 was added to the mixture which was then refluxed using 
Dean Stark apparatus for 3 hrs until all of the acid has been converted to ester (TLC: MeOH/ 
CHCl3 (1:99; v/v)). The solvent was then removed and the product was dissolved in ethyl 
acetate and extracted against water. Organic layer was dried to give 5g of 10-bromodecanoic 
acid ethyl ester (5).  
TLC [MeOH:CHCl3 1:99; v/v)], Rf (I2) = 7.1/8.5= 0.83 
Product: colorless oil 
Yield: 5g (90%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.3 (m, 10H), 1.35 (t, 3H), 1.6 (m, 2H), 1.8 (m, 2H), 2.27 
(t, 2H), 3.37 (t, 2H), 4.1 (q, 2H). 
 
Step (B): 10-triphenylphosphoniumethyldecanoate bromide salt (8). 
10-bromodecanoic acid ethyl ester (5) (4g, 14.3mmol) and (3.75g, 14.3mmol) of 
triphenylphosphine were refluxed in 25 ml dioxane for 10 days. Reaction was followed by 
TLC (CHCl3). Dioxane was evaporated to dryness and then the salt was washed with diethyl 
ether 20 ml three times. The oily layer was separated and dried under vacuum to give 7g of 
10-triphenylphosphoniumethyldecanoate bromide salt (8). 
TLC (CHCl3) Rf= 1.5/8.5= 0.18 
Product: brownish oil (gummy). 
Yield: 7g (90%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.27 (m, 19H), 1.65 (m, 2H), 2.2 (t, 2H), 4.1 (q, 2H), 
7.65-7.8 (m, 15H). 
 
Step (C): 11-phenylundec-10-enoic acid ethyl ester (16,17). 
(8) (1.5g, 2.77mmol) was dissolved in 20ml dry THF. The solution was cooled to -78 ˚C. 
Under N2 atmosphere, n-BuLi (1.6M in hexane; 2.1ml, 3.3mmol) were added drop wisely 
while the temperature was kept at -78 ˚C. When the addition of n-BuLi was completed the 
reaction was stirred at -78 ˚C for 40 minutes. At this stage, benzaldehyde (0.28ml, 2.77mmol) 
was added drop wisely and reaction was stirred for additional hour under inert atmosphere at -
78 ˚C. The reaction mixture was allowed to elevate to room temperature and the stirring 
continued for overnight. Reaction progress was mentored using TLC CHCl3: hexane (40:60; 
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v/v). When the reaction was over, it was quenched by adding 10% aqueous hydrochloric acid. 
The reaction mixture was partitioned between DCM and distilled water. The organic fractions 
were pooled and dried over anhydrous Na2SO4. After filtering off the solids desired product 
was purified using column chromatography [CHCl3: hexane (20:80; v/v)] to give 278mg of 
pure 11-phenylundec-10-enoic acid ethyl ester (16,17),  
TLC (CHCl3: hexane (40:60; v/v) Rf= 6.3 /8.5= 0.74 
Product: off-white oil.  
Yield: 0.28g (37.5%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.27(m, 8H), 1.30 (t, 3H), 1.4-1.45 (m, 2H), 1.55 (m, 2H), 
2.18-2.2 (dt, 2H), 2.34(t, 2H), 4.1 (q, 2H), 5.65(dt, 1H), 6.4 (d, 1H), 7.15-7.35 (m, 5H). 
 
4.2.2. Synthesis of 11-phenylundec-10-enoic acid (22,23). 
 (16,17) (0.051g, 0.177mmol) was hydrolyzed by 5% NaOH : MeOH –H2O (2:1; v/v), stirring 
at room temperature Reaction was followed by TLC MeOH : CHCl3 (5:95; v/v). Then it was 
acidified by 10%HCl (dropping), extracted with three portions of DCM (25 ml/each). The 
organic phase was dried and weighed 35mg of pure 11-phenylundec-10-enoic acid (22,23).  
TLC (MeOH : CHCl3 (5:95; v/v)) Rf= 2.2/7.4= 0.29 
Product: white precipitate  
Yield: 0.035g (76%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.27(m, 8H), 1.4 (m, 2H), 1.61 (m, 2H), 2.31 (dt, 2H), 
2.34 (t, 2H), 5.65(dt, 1H), 6.4(d, 1H), 7.20-7.35 (m, 5H). 
 
4.2.3. Synthesis of 11-phenylundecanoic acid (25). 
Part of 11-phenylundec-10-enoic acid (22,23) was reduced by H2(g) Pd-C at100 psi for 4 hrs 
to obtain 11-phenyl-undecanoic acid. 
 
4.2.4. Synthesis of 9-p-nitrophenyl-8-nonenoic acid (20,21) 
 
Step 1: preparation of 8-Bromo-octanoic acid methyl ester (3) 
8–Bromooctanoic acid (5g, 22.4mol) were dissolved in 15 ml methanol and 25 ml toluene and 
then 5 drops of H2SO4 was added. The mixture was refluxed using Dean Stark apparatus until 
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all of the acid has converted to ester (2-3 hrs) (TLC: MeOH/ CHCl3 (1:99; v/v)). The solvent 
was then removed and the product was dissolved in ethyl acetate and extracted against water 
and then against 5 % NaHCO3.   
TLC [MeOH:CHCl3 1:99; v/v)], Rf (I2) = 6.8/8.2= 0.83 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.3 (m, 6H), 1.66 (m, 2H), 1.8 (m, 2H), 2.27 (t, 2H), 3.35 
(t, 2H), 3.68 (s, 3H). 
  
Step 2: 8-triphenylphosphoniumethyloctanoate bromide salt (6) 
8-bromomethyloctanoate (3) (5g, 21.08mmol) and (5.5g, 21.08mmol) of PPh3 in 25ml 1,4-
dioxane were refluxed for 10 days. Reaction was followed by TLC (CHCl3). Dioxane was 
evaporated to dryness and then the salt was washed with diethyl ether 20 ml three times. The 
oily layer was separated and dried under vacuum to give the brownish gummy 8-
triphenylphosphoniumethyloctanoate bromide salt (6) 
TLC (CHCl3) Rf= 1.4/8.2= 0.17 
Product: brownish oil (gummy). 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.3 (m, 10H), 1.65 (m, 2H), 2.27 (t, 2H), 3.35 (s, 3H), 
7.3-7.6 (m, 15H). 
 
Step 3: Synthesis of 9-p-nitrophenyl-8-nonenoic acid (20,21) 
A solution of NaH (0.160g) (Sodium hydride, 60% dispersion in mineral oil) dispersed in 5ml 
dried DCM was added drop wisely at 0 °C to a solution of 8-triphenylphosphonium 
methyloctanoate bromide salt (6) (2.0g, 3.9 mmol) dissolving in 10 ml of dry DCM. When all 
of the NaH was added the mixture was warmed to room temperature and then it was refluxed 
for 1 hr. Then p-nitrobenzaldehyde (0.601g, 3.98mmol) dissolved in 10ml dried DCM was 
added drop by drop under vigorous stirring. After all the p-nitrobenzaldehyde was added the 
mixture was refluxed for additional 2 hours. After that EtOH and then water were added drop 
wisely with stirring. The solvent was then dried under vacuum and the product was dissolved 
in DCM and extracted against water. The DCM layer was purified by CC using [CHCl3: 
MeOH] as eluents to afford 9-(4-nitrooxyphenyl)-non-8-enoic acid methyl ester (Z-14, E-15). 
Then half of the product was hydrolyzed by 5% NaOH : MeOH –H2O (2:1; v/v), stirring at 
room temperature Reaction was followed by TLC MeOH : CHCl3 (5:95; v/v). Then it was 
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acidified by 10% HCl, extracted with three portions of DCM (25 ml/each). The organic phase 
was dried to give 9-(4-nitrooxyphenyl)-non-8-enoic acid (20, 21). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.3 (m,4H), 1.32-1.35 (m,2H), 1.6 (m,2H), 2.0 (dt,2H), 
2.23 (t,2H), 6.3 (dt,1H), 6.6 (d,1H), 7.61 (d,2H), 8.22 (d,2H). 
 
4.2.5. Synthesis of (9-(4-ethylphenyl)-non-8-enoic acid (18,19) 
A solution of NaH (0.093g) (Sodium hydride, 60% dispersion in mineral oil) dispersed in 5ml 
dried DCM was added drop wisely at 0 °C to a solution of 8-triphenylphosphonium 
methyloctanoate bromide salt (1.17 g,  2.28 mmol) dissolved in 10 ml of dry DCM. When all 
of the NaH was added the mixture was warmed to room temperature and then was refluxed for 
3 hrs. Then p-ethylbenzaldehyde (0.30 ml, 2.17 mmol) dissolved in 10ml dried DCM was 
added drop wisely under vigorous stirring. After all the p-ethylbenzaldehyde was added the 
mixture was refluxed for additional 2 hours. After that EtOH and then water were added drop 
wisely with stirring. The solvent was then dried under vacuum and the product was dissolved 
in DCM and extracted against water. The DCM layer was purified by CC using [CHCl3: 
MeOH] as eluents to afford (9-(4-ethylphenyl)-non-8-enoic acid methyl ester (Z-12, E-13). 
Half of the product was hydrolyzed by 5% NaOH : MeOH –H2O (2:1; v/v), stirring at room 
temperature Reaction was followed by TLC MeOH : CHCl3 (5:95; v/v). Then it was acidified 
by 10% HCl, extracted with three portions of DCM (25 ml/each). The organic phase was dried 
to (9-(4-ethylphenyl)-non-8-enoic acid (18,19). 
TLC (MeOH : CHCl3 (5:95; v/v)) Rf= 2.0/6.8= 0.29 
Product: off-white precipitate  
1
H-NMR 300 MHz (CDCl3) (ppm) 1.24 (t,3H), 1.3-1.35 (m,6H), 1.6 (m,2H), 2.0 (dt,2H), 
2.24 (t,2H), 2.6 (t,2H), 5.58 (dt,1H), 6.4 (d,1H), 7.10 (d,2H), 7.27 (d,2H). 
 
4.3. Synthesis of naphthyl-myristate analogues (subgroup C).  
  
4.3.1. Synthesis of 9-naphthalen-2-yl-non-8-enoic acid ethyl ester (28) 
Step 1: synthesis of 8-bromooctanoic acid ethyl ester (4). 
8-Bromooctanoic (1) (5g, 22.4mmol) were dissolved in ethanol 12ml (398mmol) and 25 ml of 
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toluene and 10 drops of H2SO4 was added to the mixture which was then refluxed using Dean 
Stark apparatus for 3 hrs until all of the acid has been converted to ester (TLC: MeOH/ CHCl3 
(1:99; v/v)). The solvent was then removed and the product was dissolved in ethyl acetate and 
extracted against water. Organic layer was dried to give of 8-bromooctanoic acid ethyl ester 
(4).  
TLC [MeOH:CHCl3 1:99; v/v)], Rf (I2) = 7.0/8.3= 0.84 
Product: colorless oil 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.29 (m, 6H), 1.35 (t, 3H), 1.65 (m, 2H), 1.8 (m, 2H), 
2.27 (t, 2H), 3.35 (t, 2H), 4.1 (q, 2H). 
 
Step (B): 8-triphenylphosphoniumethyloctanoate bromide salt (7). 
8-Bromooctanoic acid ethyl ester (5) (4g, 15.9mmol) and (6.9g, 15.9mmol) of 
triphenylphosphine were refluxed in 25 ml dioxane for 10 days. Reaction was followed by 
TLC (CHCl3). Dioxane was evaporated to dryness and then the salt was washed with diethyl 
ether 20ml three times. The oily layer was separated and dried under vacuum to give 8-
triphenylphosphoniumethyloctanoate bromide salt (7). 
TLC (CHCl3) Rf= 1.5/8.5= 0.18 
Product: brownish oil (gummy). 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.3 (m, 12H), 1.65 (m, 2H), 2.25 (t, 2H), 4.1 (q, 2H), 
7.3-7.6 (m, 15H). 
 
Step (C): Synthesis of 9-naphthalen-2-yl-non-8-enoic acid ethyl ester (28) 
7-Ethoxycarbonyl-heptyl)-triphenyl-phosphonium; bromide (7) (4.76g, 9.26 mmol) was 
dissolved in 20ml dry THF. The solution was cooled to -78 ˚C. Under N2 atmosphere, n-BuLi 
(1.6M in hexane; 7ml, 11.1 mmol) were added drop wisely while the temperature was kept -78 
˚C. When the addition of n-BuLi was completed the reaction was stirred at -78 ˚C for 1 hour. 
At this stage, 2-naphthaldehyde (1.45g. 9.26 mmol) was added drop wisely and reaction was 
stirred for additional hour under inert atmosphere and -78 ˚C. The reaction mixture was 
allowed to elevate to room temperature and the stirring continued for overnight. Reaction 
progress was mentored using TLC CHCl3: hexane (40:60; v/v). When the reaction was over, it 
was quenched by adding 10% aqueous hydrochloric acid. The reaction mixture was 
53 
 
partitioned between DCM and distilled water. The organic fractions were pooled and dried 
over anhydrous Na2SO4. After filtering off the solids desired product was purified using 
column chromatography [CHCl3: hexane (20:80; v/v)] to give 0.47 g of pure 9-naphthalen-2-
yl-non-8-enoic acid ethyl ester (28),  
TLC (CHCl3: hexane (20:80; v/v) Rf= 6.3 /8.5= 0.74 
Product: white precipitate  
Yield: 0.047g (1.6%). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.29 (m, 4H), 1.3 (t,3H), 1.35 (m, 2H), 1.68 (m, 2H),  
2.2 (dt, 2H), 2.3 (t, 2H), 4.1 (q, 2H), 5.80 (dt, 1H), 6.41 (d, 1H), 7.44-7.72 (m, 7H). 
 
4.3.2. Synthesis of 9-Naphthalen-2-yl-non-8-enoic acid (29)  
(28) (0.047g, 0.15mmol) was hydrolyzed by 5% NaOH : MeOH –H2O (2:1; v/v), stirring at 
room temperature Reaction was followed by TLC MeOH : CHCl3 (5:95; v/v). Then it was 
acidified by 10%HCl (dropping), extracted with three portions of DCM (25 ml/each). The 
organic phase was dried and weighed 25.8mg of 9-naphthalen-2-yl-non-8-enoic acid (29).  
TLC (MeOH : CHCl3 (5:95; v/v)) Rf= 2.8/7.4= 0.38 
Product: white precipitate  
Yield: 0.026g (65%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.29 (m, 4H), 1.35 (m, 2H), 1.68 (m, 2H),  2.2 (dt, 
2H), 2.27 (t, 2H), 5.90 (dt, 1H), 6.41 (d, 1H), 7.44-7.72 (m, 7H). 
 
4.3.3. Synthesis of 9-Naphthalen-2-yl-nonanoic acid ethyl ester (30) 
Part of 9-naphthalen-2-yl-non-8-enoic acid ethyl ester (28) was reduced by H2(g) Pd-C at100 
psi for 4 hrs to obtain 9-naphthalen-2-yl-nonanoic acid ethyl ester (30). 
 
4.4 Synthesis of group (II) myristate analogues 
 
4.4.1. Synthesis of aminoalkanoic acid ethyl esters [8-aminooctanoic acid ethyl ester (35), 
10-aminodecanoic acid ethyl ester (36), 11-aminoundecanoic acid ethyl ester (37)].  
 
General Procedure. 
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Bromoalkanoic acid (4.00mmol) [8-bromooctanoic acid (1), 10-bromodecanoic acid (2),11-
bromoundecanoic acid (31)] was dissolved in 5 equivalents NH4OH 25% (3.0ml) and stirred at 
room temperature for 48 hours. The reaction progress was followed using TLC 
(MeOH:CHCl3; 20:80; v/v; I2). When the reaction was over as indicated by the disappearance 
of the starting material the volatiles were evaporated to dryness under reduced pressure. The 
precipitate was dissolved in (15ml) EtOH neat and heated to reflux for 1 hour. The mixture 
was allowed to cool to ambient temperature and precipitates were filtered off. The precipitate 
was washed with additional 10 ml ethanol and filtrates were collected and evaporated to 
dryness to give a white precipitate of corresponding aminoalkanoic acid [8-aminooctanoic 
acid (32), 10-aminodecanoic acid (33), 11-aminoundecanoic acid (34),]. The amino acid [(32), 
(33), (34)] was then dissolved in 25ml EtOH and cooled in ice-bath, gaseous hydrochloric acid 
HCl was bubbled until the pH turned to strongly acidic (pH=1). The ice bath was removed and 
the mixture was heated reflux. The esterification was followed using TLC (MeOH: CHCl3; 
20:80; v/v; I2). When affirming the total conversion of the amino acid to ester form the 
reaction mixture was cooled to room temperature and the volatiles evaporated under reduced 
pressure to dryness. The off-white precipitate of corresponding aminoalkanoic acid ethyl ester 
[(35), (36), (37)] was collected and re-crystallized from ethanol.  
11-Aminoundecanoic acid (34). 
Product: White precipitate 
Yield: 0.80g (100%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.21 (m, 12H), 1.59 (m, 2H), 1.78 (m, 2H), 2.26 (t, 2H), 
3.01 (t, 2H). 
 
11-Aminoundecanoic acid ethyl ester (37). 
Product: Off-white precipitate 
Yield: 0.96g (91%).
 
1
H-NMR 300 MHz (CDCl3) (ppm)  1.21 (m, 12H), 1.25 (t, 3H), 1.59 (m, 2H), 1.78 (m, 2H), 
2.26 (t, 2H), 3.01 (t, 2H), 4.10 (q, 2H). 
 
4.4.2. Synthesis of 11-Arylamidoundecanoic acid ethyl ester derivatives (39, 40, 42) 
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General Procedure: 
In a 25ml round bottom flask, (0.37g, 1.5mmol) of the aromatic carboxylic acid derivative, 
(0.4g, 1.5mmol) [(37) as example], (0.34g, 1.65mmol) DCC and (0.24ml, 1.65mmol) dry 
triethylamine (TEA) were mixed in 5ml DMF. The reaction mixture was stirred at room 
temperature for the time needed for completion. The reaction progress was followed using 
TLC (CHCl3). When the reaction was completed DMF was evaporated under reduced pressure 
to dryness and the mixture was portioned between the aqueous and ethyl acetate (30mlX3). 
The organic fractioned were pooled dried over anhydrous sodium sulfate. After filtering off 
the solids the volatiles were evaporated to dryness under reduced pressure. The off-white 
powder was purified by column chromatography using CHCl3: hexane (40:60; v/v) as eluent 
to give the purified desired product.   
 
11-(4-Iodobenzoylamino)-undecanoic acid ethyl ester (40).  
TLC (CHCl3), Rf= 2.6/8.5= 0.31 
Product: white powder 
Yield: 0.44g (63.8%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.30 (m, 15H), 1.6 (m,2H), 1.69 (m, 2H),  2.2 (t, 
2H), 3.39 (m, 2H), 4.11 (q, 2H), 6.15 (s, N-H amide), 7.27 (d, 2H), 7.75 (d, 2H). 
10-(4-Iodo-benzoylamino)-decanoic acid ethyl ester (39). 
TLC (CHCl3), Rf= 2.6/8.5= 0.31 
Product: white precipitate 
Yield: 0.43g (56.6 %).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25 (m, 13H), 1.59 (m, 2H), 1.81 (m, 2H), 2.03 (t, 2H), 
3.48 (m, 2H), 4.05 (q, 2H), 6.15 (s, N-H amide), 7.25 (d, 2H), 7.74 (d, 2H). 
 
11-(3, 4 -Dimethoxybenzoylamino)-undecanoic acid ethyl ester (42). 
The crude product was purified by column chromatography CHCl3 to give a white powder of 
(42).  
TLC (CHCl3), Rf= 2.5/8.5= 0.29 
Product: white precipitate 
Yield: 0.40g (67.8%). 
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1
H-NMR 300 MHz (CDCl3) (ppm) 1.25 (m, 15H), 1.57 (m, 2H), 1.81 (m, 2H), 2.06 (t, 2H), 
3.49 (t, 2H), 3.91 (s, 6H), 4.12 (q, 2H), 6.06 (s, N-H amide), 6.85 (d, 1H), 7.12 (s, 1H), 7.18 
(d, 1H). 
 
 
4.4.3. Synthesis of 11-Benzoylaminoundecanoic acid ethyl ester (44). 
In a 25ml round bottom flask, (37) (0.4g, 1.5mmol), benzoic anhydride (43) (0.34g, 1.5mmol) 
and TEA (0.25ml, 1.8mmol) were dissolved in 10ml DMF. The reaction mixture was stirring 
at room temperature for overnight and the completion of the reaction was indicated by TLC 
CHCl3:Hexane (60: 40; v/v).The DMF was evaporated to dryness and crude product was 
extracted by CHCl3 against distilled water. The organic phase was dried by Na2SO4 and the 
solvent was removed by reduced pressure. The crude product was purified by column 
chromatography using CHCl3:Hexane (40: 60; v:v) to give 0.25g white powder of (44).  
TLC (CHCl3), Rf= 1.5/8.6= 0.17 
Product: white precipitate 
Yield: 0.25g (50%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.30 (m, 15H), 1.60 (m, 4H), 2.28 (t, 2H), 3.45 (t, 
2H), 4.12 (q, 2H), 6.10 (s, N-H amide), 7.48 (dd, 1H), 7.42 (m, 2H), 7.75(d, 2H). 
13
C-NMR (CDCl3,  ppm): 15.0, 25.0, 27.25, 29.27, 29.4, 29.5, 29.52, 29.54, 29.8, 34.9, 
40.05, 60.08, 76.8, 77.5, 77.8, 126.5, 128.0, 130.0, 131.0, 134.0, 135.0, 168.0, 172.0. 
 
4.4.4. Synthesis of 11-Benzoylaminoundecanoic acid (68). 
 (44) (1.13g) were dissolved in 10ml of NaOH 5% (EtOH:H2O; 2:1) and refluxed at 50 °C for 
30 min. Completion of the hydrolysis was monitored by TLC (CHCl3), then the reaction 
mixture was acidified and extracted by ethyl acetate, the organic phase was dried and the 
solvent was distilled off by reduced pressure to afford 1.0g of (68) as a white powder. 
Product: white powder 
Yield: 1.00g (96.6%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.30 (m, 15H), 1.61 (m, 4H), 2.34 (t, 2H), 3.44 (t, 2H), 
6.10 (s, N-H amide), 7.42 (m, 3H), 7.74 (d, 2H). 
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4.4.5. Synthesis of N-(10-Propylcarbamoyldecyl)-benzamide (71). 
In a 25ml round bottom flask, (68) (0.2g, 0.65mmol), NHS (0.075g, 0.65mmol) and DCC 
(0.15g, 0.715mmol) were dissolved in DMF (5ml as a solvent). The reaction mixture was 
stirring at room temperature for overnight, the completion of the reaction was indicated by 
TLC (CHCl3). Then propyl amine (0.06ml, 0.72mmol) was added to the mixture under the 
same condition. DMF was evaporated to dryness; crude product was extracted by Ethyl acetate 
against distilled water. The organic fractions were collected and dried by Na2SO4. After 
filtering off the solids the solvent was removed under reduced pressure to one tenth of original 
volume. Mixture was then filtered to give a 0.137g white powder (71).  
TLC (CHCl3), Rf= 1/8.5= 0.12 
Product: white powder 
Yield: 0.137g (62.3%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 0.90 (t, 3H), 1.30 (m, 12H), 1.60 (m, 6H), 3.2 (q, 2H), 
3.44 (q, 2H), 5.5 (s, N-H amide), 6.23 (s, N-H amide), 7.43 (d, 3H), 7.76 (d, 2H). 
 
4.4.6. Synthesis of 11-[2-(4-fluoro-phenyl)-acetylamino]-undecanoic acid ethyl ester (46). 
In a 25ml round bottom flask, (37) (0.4g, 1.5mmol), (4-fluorophenyl)-acetic acid (45) (0.24g, 
1.5mmol), DCC (0.34g, 1.65mmol) and TEA (0.23ml, 1.65mmol) were dissolved in 5ml 
DMF. The reaction mixture was stirring at room temperature for overnight and the completion 
of the reaction was indicated by TLC (CHCl3). The DMF was evaporated to dryness; crude 
product was extracted by ethyl acetate against distilled water. The organic fractions were 
collected and dried by Na2SO4. After filtering off the solids the solvent was removed under 
reduced pressure. The crude product was purified by column chromatography using CHCl3: 
Hexane (40: 60; v/v) to give 75mg of (46) as a white powder.  
TLC (CHCl3), Rf= 1.7/8.5= 0.2 
Product: yellowish precipitate 
Yield: 0.15g (27.8%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.30 (m, 15H), 1.6 (m, 4H), 2.26 (t, 2H), 3.19 (m, 
2H), 3.51 (s, 2H), 4.10 (q, 2H), 5.36 (s, N-H amide), 7.02 (d, 2H), 7.21 (d, 2H). 
 
4.4.7. Synthesis of 11-[4-(4-Fluorophenyl)-4-oxobutyrylamino]-undecanoic acid ethyl 
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ester (48).   
In a 25ml round bottom flask, (37) (0.4g, 1.5mmol), 4-(4-fluorophenyl)-4-oxobutanoic acid 
(47) (0.29g, 1.5mmol), DCC (0.25g, 1.65mmol) and TEA (0.23ml, 1.65mmol) were dissolved 
in 5ml DMF. The reaction mixture was stirring at room temperature for overnight and the 
completion of the reaction was indicated by TLC (CHCl3). Then DMF was evaporated to 
dryness, product was extracted by ethyl acetate against distilled water, the organic phase was 
dried by Na2SO4 and the solvent was removed by reduced pressure to afford a mixture as a 
yellowish solution. The crude product was purified by column chromatography using CHCl3: 
Hexane (40:60 v/v) to give 0.32g yellowish powder of (48).  
TLC (CHCl3), Rf= 1.7/8.5= 0.2 
Product: yellowish powder 
Yield: 0.32g (40%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.27(m, 15H), 1.79(m, 2H), 1.98(m, 2H),  2.79(t, 2H), 
3.38(t, 4H), 3.71(m, 2H), 4.1(q, 2H), 7.15(d, 2H), 8.03(d, 2H). 
 
4.4.8. Synthesis of 11-[(Naphthalene-2-carbonyl)-amino]-undecanoic acid ethyl ester (51). 
In a 25ml round bottom flask, (37) (0.40g, 1.5mmol), 1-naphthoic acid (49) (0.28g, 
1.65mmol), DCC (0.34g, 1.65mmol) and TEA (0.23ml, 1.65mmol) were dissolved in 5ml 
DMF. The reaction mixture was stirring at room temperature for overnight and the completion 
of the reaction was indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product 
was extracted by ethyl acetate against distilled water, the organic phase was dried by Na2SO4 
and the solvent was removed by reduced pressure to afford a mixture as an off-white powder. 
The crude product was purified by column chromatography using 100% CHCl3 to give a white 
powder of (51).  
TLC (CHCl3), Rf= 6/8.7= 0.69 
Product: white powder 
Yield: 0.52g (90%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25 (m, 15H), 1.57 (m, 2H), 1.83 (m, 2H), 2.16 (t, 2H), 
3.48 (t, 2H), 3.88 (q, 2H), 7.15 (s, N-H amide), 7.43-7.50 (d, 2H), 7.57 (d, 2H), 7.88 (d, 2H), 
7.91 (s, 1H). 
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4.4.9. Synthesis of 10-[(Naphthalene-2-carbonyl)-amino]-decanoic acid ethyl ester (50). 
In a 25ml round bottom flask, (36) (0.40g, 1.59mmol), (49) (0.27g, 1.59mmol), DCC (0.36g, 
1.75mmol) and TEA (0.24ml, 1.75mmol) were dissolved in 5ml DMF. The reaction mixture 
was stirring at room temperature for overnight and the completion of the reaction was 
indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product was extracted by 
ethyl acetate against distilled water, the organic phase was dried by Na2SO4 and the solvent 
was removed by reduced pressure to afford a mixture as an off-white powder. The crude 
product was purified by column chromatography using 100% CHCl3 to give 0.45g white 
powder of (50).  
TLC (CHCl3), Rf= 4.2/9= 0.47 
Product: white powder 
Yield: 0.45g (76%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25 (m, 13H), 1.50 (m, 2H), 1.73 (m, 2H), 2.13 (t, 2H), 
3.43 (t, 2H), 3.86 (q, 2H), 7.00 (s, N-H amide), 7.23 (dd, 2H), 7.42 (d, 2H), 7.52 (d, 2H), 7.87 (s, 
1H). 
 
4.4.10. Synthesis of 11-(4-Trifluoromethylbenzoylamino)-undecanoic acid ethyl ester 
(55). 
In a 25ml round bottom flask, (37) (0.40g, 1.5mmol), 4-trifluoromethyl-benzoic acid (52) 
(0.28g, 1.5mmol), DCC (0.34g, 1.65mmol) and TEA (0.23ml, 1.65mmol) were dissolved in 
5ml DMF. The reaction mixture was stirring at room temperature for overnight and the 
completion of the reaction was indicated by TLC (CHCl3). Then DMF was evaporated to 
dryness, product was extracted byethyl acetate against distilled water the organic phase was 
dried by Na2SO4 and the solvent was removed by reduced pressure to afford a mixture as an 
off-white powder. The crude product was purified by column chromatography using 100% 
CHCl3 to give (55) as a white precipitate.  
TLC (CHCl3), Rf= 2.7/8.8= 0.31 
Product: white precipitate 
Yield: 0.095g (24%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.30 (m, 15H), 1.57 (m, 2H), 1.80 (m, 2H),  2.00 (t, 
2H), 3.48 (m, 2H), 4.1 (q, 2H), 6.08 (s, N-H amide), 7.66 (d, 4H). 
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4.4.11. Synthesis of 10-(4-Trifluoromethylbenzoylamino)-decanoic acid ethyl ester (54). 
In a 25ml round bottom flask, (36) (0.40g, 1.59mmol), (52) (0.30g, 1.59mmol), DCC (0.36g, 
1.75mmol) and TEA (0.24ml, 1.75mmol) were dissolved in 5ml DMF. The reaction mixture 
was stirring at room temperature for overnight and the completion of the reaction was 
indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product was extracted by 
Ethyl acetate against distilled water, the organic phase was dried by Na2SO4 and the solvent 
was removed by reduced pressure to afford a mixture as an off-white powder. The crude 
product was purified by column chromatography using 100% CHCl3 to give 0.33g (54) as a 
white powder.  
TLC (CHCl3), Rf= 2.7/8.8= 0.31 
Product: white precipitate 
Yield: 0.33g (53.8%).
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25-1.30 (m, 13H), 1.49 (m, 2H), 1.76 (m, 2H),  2.00 (t, 
2H), 3.44 (m, 2H), 4.1 (q, 2H), 6.08 (s, N-H amide), 7.20 (d, 2H), 7.61 (d, 2H). 
 
4.4.12. Synthesis of 8-(4-Trifluoromethyl-benzoylamino)-octanoic acid ethyl ester (53). 
In a 25 ml one-necked flask were charged, the residue of 8-aminooctanoic acid ethyl ester (35) 
(0.5 g, 2.23 mmol), ,,-triflouro-P-toluic acid (52) (0.423g, 2.23mmol), DCC ( 0.475g, 
2.23mmol) TEA (0.306ml, 2.25mmol) and ethyl acetate (5ml as solvent). The reaction mixture 
was stirring at room temperature for 36hours, the completion of the reaction was indicated by 
TLC (100% CHCl3), the mixture was filtered, and the solvent was distilled off by reduced 
pressure, the residue was purified by column chromatography 100% CHCl3.     
TLC (CHCl3), Rf= 2.3/8.2= 0.28 
Product: white precipitate 
Yield: 0.40g (50%). 
NMR results : 1H-NMR (300 MHz, CDCl3): (ppm) 1.2 (t, 3H), 1.6 (m, 8H), 1.7(m, 4H), 2.3 (t, 
2H), 2.7 (t, 2H), 3.5(q, 2H), 4.1 (q, 2H), 6.2 (brd, N-H amide),  7.7 (d, 2H), 7.9 (d, 2H). 
 
4.4.13. Synthesis of 8-(4-Trifluoromethyl-benzoylamino)-octanoic acid (69) 
In a 25ml round bottom flask, (53) (0.05 g, 46mmol) were dissolved in 10ml of NaOH 5% 
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(EtOH:H2O; 2:1) and refluxed at 50 °C for 30 min. Completion of the hydrolysis was 
monitored by TLC (CHCl3), then the reaction mixture was acidified and extracted by ethyl 
acetate, the organic phase was dried and the solvent was distilled off by reduced pressure to 
afford (69) as an off- white powder. 
NMR results: 1H-NMR (300 MHz, CDCl3): (ppm), 1.6 (m, 8H), 1.7(m, 4H), 2.3 (t, 2H), 2.3 (t, 
2H), 3.5(q, 2H), 6.2 (brd, N-H amide),  7.7 (d, 2H), 7.9 (d, 2H). 
 
4.4.14. Synthesis of 11-(3-Chlorobenzoylamino)-undecanoic acid ethyl ester (59). 
In a 25ml round bottom flask, (37) (0.40g, 1.5mmol), 3-chlorobenzoic acid (56) (0.32g, 
1.65mmol), DCC (0.34g, 1.65mmol) and TEA (0.23ml, 1.65mmol) were dissolved in 5ml 
DMF. The reaction mixture was stirring at room temperature for overnight and the completion 
of the reaction was indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product 
was extracted by ethyl acetate against distilled water, the organic phase was dried by Na2SO4 
and the solvent was removed by reduced pressure to afford a mixture as an off-white powder. 
The crude product was purified by column chromatography using 100% CHCl3 to give (59) 
with some impurities of DCU which was then re-crystallized by ethyl acetate to afford 0.20g 
of (59) as a white powder.  
TLC (CHCl3), RF= 1.7/8.8= 0.19 
Product: white powder 
Yield: 0.20 g (36%). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25 (m, 15H), 1.59 (m, 2H), 1.83 (m, 2H), 2.02 (t, 2H), 
3.50 (t, 2H), 4.07 (q, 2H), 6.03 (s, N-H amide), 7.35 (dd, 1H), 7.42 (d, 2H), 7.53 (s, 1H). 
 
4.4.15. Synthesis of 10-(3-Chlorobenzoylamino)-decanoic acid ethyl ester (58). 
In a 25ml round bottom flask, (36) (0.40g, 1.59mmol), (56) (0.25g, 1.59mmol), DCC (0.36g, 
1.75mmol) and TEA (0.24ml, 1.75mmol) were dissolved in 5ml DMF. The reaction mixture 
was stirring at room temperature for overnight and the completion of the reaction was 
indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product was extracted by 
ethyl acetate against distilled water, the organic phase was dried by Na2SO4 and the solvent 
was removed by reduced pressure to afford a mixture as an off-white powder. The crude 
product was purified by column chromatography using 100% CHCl3 to give (58) 0.39g as a 
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white powder.  
TLC (CHCl3), Rf= 1.7/8.8= 0.19 
Product: white powder 
Yield: 0.39g (69.3%). 
 
1
H-NMR 300 MHz (CDCl3)  (ppm) 1.25 (m, 13H), 1.59 (m, 2H), 1.83 (m, 2H), 2.02 (t, 2H), 
3.50 (t, 2H), 4.07 (q, 2H), 6.03 (s, N-H amide), 7.35 (dd, 1H), 7.42 (d, 2H), 7.53 (s, 1H). 
 
4.4.16. Synthesis of  8-(3-Chlorobenzoylamino)-octanoic acid ethyl ester (57). 
In a 25ml round bottom flask, 8-aminooctanoic acid ethyl ester (35) (0.40g, 1.7mmol), (56) 
(0.28g, 1.7mmol), DCC (0.38g, 1.87mmol) and TEA (0.26ml, 1.87mmol) were dissolved in 
5ml DMF. The reaction mixture was stirring at room temperature for overnight and the 
completion of the reaction was indicated by TLC (CHCl3). Then DMF was evaporated to 
dryness, product was extracted by ethyl acetate against distilled water, the organic phase was 
dried by Na2SO4 and the solvent was removed by reduced pressure to afford a mixture as an 
off-white powder. The crude product was purified by column chromatography using 100% 
CHCl3 to give 0.42g (57).  
TLC (CHCl3), Rf= 2.1/8.8= 0.24 
Product: white powder 
Yield: 0.34g (57.9%). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.20 (m, 9H), 1.60 (m, 2H), 1.82 (m, 2H), 2.02 (t, 2H), 
3.50 (t, 2H), 4.09 (q, 2H), 6.05 (s, N-H amide), 7.35 (dd, 1H), 7.42 (d, 2H), 7.53 (s, 1H). 
 
4.4.17. Synthesis of 11-[(Biphenyl-4-carbonyl)-amino]-undecanoic acid ethyl ester (61). 
In a 25ml round bottom flask, (37) (0.40g, 1.5mmol), biphenyl-4-carboxylic acid (60) (0.22g, 
1.5mmol), DCC (0.34g, 1.65mmol) and TEA (0.23ml, 1.65mmol) were dissolved in 5ml 
DMF. The reaction mixture was stirring at room temperature for overnight and the completion 
of the reaction was indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product 
was extracted by ethyl acetate against distilled water, the organic phase was dried by Na2SO4 
and the solvent was removed by reduced pressure to afford a mixture as an off-white powder. 
The crude product was purified by column chromatography using 100% CHCl3 to give (61) as 
a white powder.  
63 
 
TLC (CHCl3), Rf= 2.8/9= 0.31 
Product: white powder 
Yield: 0.6g (96.8%). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.21-1.30 (m, 15H), 1.55 (m, 2H), 1.82 (m, 2H),  2.05 (t, 
2H), 3.52 (m, 2H), 4.13 (q, 2H), 6.16 (s, N-H amide), 7.44 (d, 3H), 7.62 (d, 4H). 
 
4.4.18. Synthesis of 11-(4-Ethylbenzoylamino)-undecanoic acid ethyl ester (65). 
In a 25ml round bottom flask, (37) (0.40g, 1.5mmol), 4-ethyl-benzoic acid (62) (0.22g, 
1.5mmol), DCC (0.34g, 1.65mmol) and TEA (0.24ml, 1.65mmol) were dissolved in 5ml 
DMF. The reaction mixture was stirring at room temperature for overnight and the completion 
of the reaction was indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product 
was extracted by ethyl acetate against distilled water, the organic phase was dried by Na2SO4 
and the solvent was removed by reduced pressure to afford a mixture as an off-white powder. 
The crude product was purified by column chromatography using 100% CHCl3 to give 0.33g 
white powder of (65). 
TLC (CHCl3), Rf= 2.5/8.7= 0.29 
Product: white powder 
Yield: 0.33g (61.8%). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 0.85 (t, 3H), 1.21-1.30 (m, 15H), 1.52 (m, 2H), 1.78 (m, 
2H),  2.28 (t, 2H), 2.66 (q, 2H), 3.47 (t, 2H), 4.11 (q, 2H), 6.06 (s, N-H amide), 7.23 (d, 2H), 
7.44 (d, 2H). 
 
4.4.19. Synthesis of 10-(4-Ethylbenzoylamino)-decanoic acid ethyl ester (64). 
In a 25ml round bottom flask, (36) (0.40g, 1.58mmol), (62) (0.24g, 1.58mmol), DCC (0.36g, 
1.7mmol) and TEA (0.24ml, 1.7mmol) were dissolved in 5ml DMF. The reaction mixture was 
stirring at room temperature for overnight and the completion of the reaction was indicated by 
TLC (100% CHCl3). Then DMF was evaporated to dryness, product was extracted by ethyl 
acetate against distilled water, the organic phase was dried by Na2SO4 and the solvent was 
removed by reduced pressure to afford a mixture as an off-white powder. The crude product 
was purified by column chromatography using 100% CHCl3 to give 0.25g of (64). 
TLC (CHCl3), Rf= 2.5/8.7= 0.29 
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Product: white powder 
Yield: 0.25g (44.6%). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 0.85 (t, 3H), 1.26 (m, 13H), 1.58 (m, 2H), 1.80 (m, 2H),  
2.12 (t, 2H), 2.65 (q, 2H), 3.46 (t, 2H), 4.12 (q, 2H), 6.06 (s, N-H amide), 7.24 (d, 2H), 7.45 (d, 
2H). 
 
4.4.20. Synthesis of 8-(4-Ethyl-benzoylamino)-octanoic acid ethyl ester. (63) 
In a 25 ml one-necked round bottom flask (35) (0.5 g, 2.23 mmol), (62) (0.335g, 2.23mmol), 
DCC ( 0.475g, 2.23mmol) and TEA (0.306ml, 2.25mmol) were dissolved in 5ml DMF The 
reaction mixture was stirring at room temperature for 36hr, The completion of the reaction 
was indicated by TLC (100% CHCl3), the mixture was filtered, and the solvent was distilled-
off by reduced pressure, the residue was purified by column chromatography (100% CHCl3). 
TLC (CHCl3), Rf= 2.1/8.2= 0.26 
Product: white powder 
NMR results : 1H-NMR (300 MHz, CDCl3): (ppm)  1.3 (m, 6H), 1.6 (m, 6H), 1.8(m, 4H), 2.2 
(t, 2H), 2.7 (q, 2H), 3.5(q, 2H), 4.05 (q, 2H), 6.2 (brd, N-H amide),  7.2 (d, 2H), 7.5 (d, 2H). 
 
4.4.21. Synthesis of 8-(4-Ethyl-benzoylamino)-octanoic acid (70) 
In a 25ml round bottom flask, (63) (0.05g, 46mmol) were dissolved in 10ml of NaOH 5% 
(EtOH:H2O; 2:1) and refluxed at 50 °C for 30 min. Completion of the hydrolysis was 
monitored by TLC (CHCl3), then the reaction mixture was acidified and extracted by ethyl 
acetate, the organic phase was dried and the solvent was distilled off by reduced pressure to 
afford (70). 
Product: white powder 
NMR results : 1H-NMR (300 MHz, CDCl3): (ppm)  1.2 (m, 6H), 1.3 (m, 6H), 1.6(m, 4H), 2.3 
(t, 2H), 2.68 (q, 2H), 3.4(q, 2H), 6.2 (brd, N-H amide),  7.2 (d, 2H), 7.6 (d, 2H). 
 
4.4.22. Synthesis of 10-(2-Iodo-benzoylamino)-decanoic acid ethyl ester (67). 
In a 25ml round bottom flask, (36) (0.40g, 1.58mmol), 2-iodobenzoic acid (66) (0.38g, 
1.58mmol), DCC (0.36g, 1.7mmol) and TEA (0.24ml, 1.7mmol) were dissolved in 5ml DMF. 
The reaction mixture was stirring at room temperature for overnight and the completion of the 
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reaction was indicated by TLC (CHCl3). Then DMF was evaporated to dryness, product was 
extracted by CHCl3 against distilled water, the organic phase was dried by Na2SO4 and the 
solvent was removed by reduced pressure to afford a mixture as an off-white powder. The 
crude product was purified by column chromatography using 100% CHCl3 to give (67).  
TLC (CHCl3), Rf= 3.8/8.5= 0.44 
Product: white precipitate 
Yield: 0.24g (34.3%). 
 
1
H-NMR 300 MHz (CDCl3) (ppm) 1.25(m, 13H), 1.58 (m, 2H), 1.80 (m, 2H),  2.1 (t, 2H), 
3.50 (t, 2H), 4.12 (q, 2H), 7.08 (, 1H), 7.26 (d, 1H), 7.40 (d, 1H), 7.83 (d, 1H). 
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